



Universiteit  
Leiden  
The Netherlands

## **Comprehensive extraction and NMR-based Metabolomics : novel approaches to natural products lead finding in drug discovery**

Yuliana, N.D.

### **Citation**

Yuliana, N. D. (2011, June 9). *Comprehensive extraction and NMR-based Metabolomics : novel approaches to natural products lead finding in drug discovery*. Retrieved from <https://hdl.handle.net/1887/17704>

Version: Not Applicable (or Unknown)

License: [Leiden University Non-exclusive license](#)

Downloaded from: <https://hdl.handle.net/1887/17704>

**Note:** To cite this publication please use the final published version (if applicable).

## References

---

1. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. *J Nat Prod* 2007; 70: 461-477.
2. Bailey NJC, Sampson J, Hylands PJ, Nicholson JK, Holmes E. Multi-component metabolic classification of commercial feverfew preparations via High-Field  $^1\text{H}$ -NMR spectroscopy and chemometrics. *Planta Med* 2002; 68: 734-738.
3. Bailey NJC, Wang Y, Sampson J, Davis W, Whitcombe I, Hylands PJ, Croft SL, Holmes E. Prediction of anti-plasmodial activity of *Artemisia annua* extracts: application of  $^1\text{H}$  NMR spectroscopy and chemometrics. *J Pharm Biomed Anal* 2004; 35: 117-126.
4. Roos G, Röseler C, Büter KB, Simmen U. Classification and correlation of St. John's Wort extracts by Nuclear Magnetic Resonance spectroscopy, Multivariate Data Analysis and pharmacological activity. *Planta Med* 2004; 70: 771-777.
5. Cardoso-Taketa AT, Pereda-Miranda R, Choi YH, Verpoorte R, Villarreal ML. Metabolic profiling of the Mexican anxiolytic and sedative plant *Galphimia glauca* using Nuclear Magnetic Resonance spectroscopy and Multivariate Data Analysis. *Planta Med* 2008; 74: 1295-1301.
6. Chiesi M, Huppertz C, Hofbauer KG. Pharmacotherapy of obesity: targets and perspectives. *Trends Pharmacol Sci* 2001; 22: 247-254.
7. Barakat H, Davis J, Lang D, Mustafa SJ, McConnaughey MM. Differences in the expression of the adenosine A1 receptor in adipose tissue of obese black and white women. *J Clin Endocrinol Metab* 2006; 91: 1882-1886.
8. Johansson SM, Lindgren E, Yang J-N, Herling AW, Fredholm BB. Adenosine A1 receptors regulate lipolysis and lipogenesis in mouse adipose tissue - Interactions with insulin. *Eur J Pharmacol* 2008; 597: 92-101.
9. Cota D, Marsicano G, Tschöp M, Grübler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thöne-Reineke C, Ortmann S. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. *J Clin Invest* 2003; 112: 423-431.
10. Kirchgesner T, Uysal K, Wiesbrock S, Marino M, Hotamisligil G. Tumor necrosis factor- $\alpha$  contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes. *J Clin Invest* 1997; 100: 2777.
11. Schripsema J, Verpoorte R. Investigation of extracts of plant cell cultures by proton nuclear magnetic resonance spectroscopy. *Phytochemical Analysis* 1991; 2: 155-162.
12. Colquhoun IJ. Use of NMR for metabolic profiling in plant systems. *J Pestic Sci* 2007; 32: 200-212.
13. Verpoorte R, Choi Y, Kim H. NMR-based metabolomics at work in phytochemistry. *Phytochem Rev* 2007; 6: 3-14.
14. Wold S, Sjöström M, Eriksson L. PLS-regression: a basic tool of chemometrics. *Chemom Intell Lab Syst* 2001; 58: 109-130.
15. Eriksson L, Johansson E, Kettaneh-Wold N, Wold S. Multi and Megavariate Data Analysis. Umeå, Sweden: Umetrics AB 2006.
16. Haslam DW, James WPT. Obesity. *Lancet* 2005; 366: 1197-1209.
17. Chaput J, St-Pierre S, Tremblay A. Currently available drugs for the treatment of obesity: Sibutramine and Orlistat. *Mini Rev Med Chem* 2007; 7: 3-10.
18. Hofbauer KG, Nicholson JR, Boss O. The obesity epidemic: Current and future pharmacological treatments. *Annu Rev Pharmacol Toxicol* 2007; 47: 565-592.
19. Bessesen DH. Update on obesity. *J Clin Endocrinol Metab* 2008; 93: 2027-2034.
20. Kumanyika S, Jeffery RW, Morabia A, Ritenbaugh C, Antipatis VJ. Obesity prevention: the case for action. *Int J Obes* 2002; 26: 425-436.
21. Comuzzie AG, Allison DB. The search for human obesity genes. *Science* 1998; 280: 1374-1377.
22. Boutin P, Froguel P. Genetics of human obesity. *Best Pract Res Clin Endocrinol Metab* 2001; 15: 391-404.
23. Loos RJF, Bouchard C. Obesity - is it a genetic disorder? *J Intern Med* 2003; 254: 401-425.
24. Bell CG, Walley AJ, Froguel P. The genetics of human obesity. *Nat Rev Genet* 2005; 6: 221-234.
25. Farooqi IS, O'Rahilly S. New advances in the genetics of early onset obesity. *Int J Obes* 2005; 29: 1149-1152.
26. Friedman JM. Obesity in the new millennium. *Nature* 2000; 404: 632-634.
27. Kopelman PG. Obesity as a medical problem. *Nature* 2000; 404: 635-643.
28. Pi-Sunyer FX. Why drugs? In: Wilding JP (ed.). *Pharmacotherapy of Obesity*. Birkhauser Verlag: Basel 2008; 1-10.

## References

29. WHO. Obesity: Preventing and managing the global epidemic: Report of a WHO consultation on obesity, Geneva, 3-5 June 1997. World Health Organization: 1998.
30. Karlsson J, Taft C, Ryden A, Sjostrom L, Sullivan M. Ten-year trends in health-related quality of life after surgical and conventional treatment for severe obesity: the SOS intervention study. *Int J Obes* 2007; 31: 1248-1261.
31. Atkinson T. Central and peripheral neuroendocrine peptides and signalling in appetite regulation: considerations for obesity pharmacotherapy. *Obes Rev* 2008; 9: 108-120.
32. Bray GA. Some historical aspects of drug treatment for obesity. In: Wilding JP (ed.). *Pharmacotherapy of Obesity*. Birkhauser Verlag: Basel 2008; 11-19.
33. Balunas MJ, Kinghorn AD. Drug discovery from medicinal plants. *Life Sci* 2005; 78: 431-441.
34. Harvey A. Natural products as a screening resource. *Curr Opin Chem Biol* 2007; 11: 480-484.
35. Moro CO, Basile G. Obesity and medicinal plants. *Fitoterapia* 2000; 71: S73-S82.
36. Pittler MH, Ernst E. Dietary supplements for body-weight reduction: a systematic review. *Am J Clin Nutr* 2004; 79: 529-536.
37. Dwyer JT, Allison DB, Coates PM. Dietary supplements in weight reduction. *J Am Diet Assoc* 2005; 105: 80-86.
38. Pittler MH, Ernst E. Complementary therapies for reducing body weight: a systematic review. *Int J Obes Relat Metab Disord* 2005; 29: 1030-1038.
39. Birari RB, Bhutani KK. Pancreatic lipase inhibitors from natural sources: unexplored potential. *Drug Discov Today* 2007; 12: 879-889.
40. Blanck HM, Serdula MK, Gillespie C, Galuska DA, Sharpe PA, Conway JM, Khan LK, Ainsworth BE. Use of nonprescription dietary supplements for weight loss is common among Americans. *J Am Diet Assoc* 2007; 107: 441-447.
41. Diepvens K, Westerterp KR, Westerterp-Plantenga MS. Obesity and thermogenesis related to the consumption of caffeine, ephedrine, capsaicin, and green tea. *Am J Physiol Regul Integr Comp Physiol* 2007; 292: R77-85.
42. Bray GA, Tartaglia LA. Medicinal strategies in the treatment of obesity. *Nature* 2000; 404: 672-677.
43. Atkinson TJ. Central and peripheral neuroendocrine peptides and signalling in appetite regulation: considerations for obesity pharmacotherapy. *Obes Rev* 2008; 9: 108-120.
44. Neary NM, Goldstone AP, Bloom SR. Appetite regulation: From the gut to the hypothalamus. *Clin Endocrinol (Oxf)* 2004; 60: 153-160.
45. Blundell J, Goodson S, Halford J. Regulation of appetite: role of leptin in signalling systems for drive and satiety. *Int J Obes* 2001; 25: 29-34.
46. Billington CJ, Levine AS. Appetite regulation: Shedding new light on obesity. *Curr Biol* 1996; 6: 920-923.
47. Schwartz MW, Woods SC, Porte D, Seeley RJ, Baskin DG. Central nervous system control of food intake. *Nature* 2000; 404: 661-671.
48. Erlanson-Albertsson C. Appetite regulation and energy balance. *Acta Paediatr* 2005; 94: 40-41.
49. Wynne K, Stanley S, McGowan B, Bloom S. Appetite control. *J Endocrinol* 2005; 184: 291-318.
50. Chaudhri O, Small C, Bloom S. Gastrointestinal hormones regulating appetite. *Philos Trans R Soc Lond B Biol Sci* 2006; 361: 1187-1209.
51. Dhillon WS. Appetite regulation: An overview. *Thyroid* 2007; 17: 433-445.
52. Näslund E, Hellström PM. Appetite signaling: From gut peptides and enteric nerves to brain. *Physiol Behav* 2007; 92: 256-262.
53. Murphy KG, Bloom SR. Gut hormones and the regulation of energy homeostasis. *Nature* 2006; 444: 854-859.
54. Broberger C, Johansen J, Johansson C, Schalling M, Hokfelt T. The neuropeptide Y/agouti gene-related protein (AGRP) brain circuitry in normal, anorectic, and monosodium glutamate-treated mice. *P Natl Acad Sci USA* 1998; 95: 15043-15048.
55. Elias C, Lee C, Kelly J, Aschkenasi C, Ahima R, Couceyro P, Kuhar M, Saper C, Elmquist J. Leptin activates hypothalamic CART neurons projecting to the spinal cord. *Neuron* 1998; 21: 1375-1385.
56. Batterham R, Cowley M, Small C, Herzog H, Cohen M, Dakin C, Wren A, Brynes A, Low M, Ghatel M. Gut hormone PYY 3-36 physiologically inhibits food intake. *Nature* 2002; 418: 650-654.
57. Hahn T, Breininger J, Baskin D, Schwartz M. Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons. *Nat Neurosci* 1998; 1: 271-272.
58. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone releasing acylated peptide from stomach. *Nature* 1999; 402: 656-660.
59. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S. A role for ghrelin in the central regulation of feeding. *Nature* 2001; 409: 194-197.

60. Ritter RC, Covasa M, Matson CA. Cholecystokinin: proofs and prospects for involvement in control of food intake and body weight. *Neuropeptides* 1999; 33: 387-399.
61. Elmquist JK, Elias CF, Saper CB. From lesions to leptin: Hypothalamic control of food intake and body weight. *Neuron* 1999; 22: 221-232.
62. Erlanson-Albertsson C. How palatable food disrupts appetite regulation. *Basic Clin Pharmacol Toxicol* 2005; 97: 61-73.
63. Cota D, Marsicano G, Lutz B, Vicennati V, Stalla G, Pasquali R, Pagotto U. Endogenous cannabinoid system as a modulator of food intake. *Int J Obes* 2003; 27: 289-301.
64. Kirkham T, Williams C. Synergistic effects of opioid and cannabinoid antagonists on food intake. *Psychopharmacologia* 2001; 153: 267-270.
65. Seeley R, York D. Fuel sensing and the central nervous system (CNS): implications for the regulation of energy balance and the treatment for obesity. *Obes Rev* 2005; 6: 259-265.
66. Levin BE, Dunn-Meynell AA, Routh VH. Brain glucose sensing and body energy homeostasis: role in obesity and diabetes. *Am J Physiol Regul Integr Comp Physiol* 1999; 276: R1223-1231.
67. López M, Tovar S, Vázquez MJ, Nogueiras R, Señaris R, Diéguez C. Sensing the fat: Fatty acid metabolism in the hypothalamus and the melanocortin system. *Peptides* 2005; 26: 1753-1758.
68. Van haelen M, Van haelen-Fastre R, But P, Van herweghem J-L. Identification of aristolochic acid in Chinese herbs. *The Lancet* 1994; 343: 174-174.
69. Obici S, Feng Z, Arduini A, Conti R, Rossetti L. Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production. *Nat Med* 2003; 9: 756-761.
70. Minokoshi Y, Alquier T, Furukawa N, Kim Y, Lee A, Xue B, Mu J, Foulfelle F, Ferré P, Birnbaum M. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. *Nature* 2004; 428: 569-574.
71. Cota D, Proulx K, Smith KAB, Kozma SC, Thomas G, Woods SC, Seeley RJ. Hypothalamic mTOR signaling regulates food intake. *Science* 2006; 312: 927-930.
72. Lee RA, Balick MJ. Indigenous use of *Hoodia gordonii* and appetite suppression. *Explore* 2007; 3: 404-406.
73. van Heerden FR, Marthinus Horak R, Maharaj VJ, Vleggaar R, Senabe JV, Gunning PJ. An appetite suppressant from *Hoodia* species. *Phytochemistry* 2007; 68: 2545-2553.
74. Rumalla C, Avula B, Shukla Y, Wang Y, Pawar R, Smillie T, Khan I. Chemical fingerprint of *Hoodia* species, dietary supplements, and related genera by using HPTLC. *J High Res Chrom* 2008; 31: 3959-3964.
75. MacLean DB, Luo L-G. Increased ATP content/production in the hypothalamus may be a signal for energy-sensing of satiety: studies of the anorectic mechanism of a plant steroidal glycoside. *Brain Res* 2004; 1020: 1-11.
76. Kumar A, Vimalavathini R. Possible anorectic effect of methanol extract of *Benincasa hispida* (Thunb). Cogn, fruit. *Indian J Pharmacol* 2004; 36: 348-350.
77. Rukumani R, Nidya I, Suresh Nair A. Investigation of anxiolytic like effect of antidepressant activity of *Benincasa hispida*, methanol extract. *Indian J Pharmacol* 2003; 35: 129-130.
78. Kumarnsit E, Keawpradub N, Nuankaew W. Acute and long-term effects of alkaloid extract of *Mitragyna speciosa* on food and water intake and body weight in rats. *Fitoterapia* 2006; 77: 339-345.
79. Thongpradichote S, Matsumoto K, Tohda M, Takayama H, Aimi N, Sakai S, Watanabe H. Identification of opioid receptor subtypes in antinociceptive actions of supraspinally-administered mitragynine in mice. *Life Sci* 1998; 62: 1371-1378.
80. Matsumoto K, Mizowaki M, Suchitra T, Murakami Y, Takayama H, Sakai S, Aimi N, Watanabe H. Central antinociceptive effects of mitragynine in mice: contribution of descending noradrenergic and serotonergic systems. *Eur J Pharmacol* 1996; 317: 75-81.
81. Matsumoto K, Mizowaki M, Takayama H, Sakai S, Aimi N, Watanabe H. Suppressive effect of mitragynine on the 5-methoxy-N, N-dimethyltryptamine-induced head-twitch response in mice. *Pharmacol Biochem Behav* 1997; 57: 319-323.
82. Babu K, McCurdy C, Boyer E. Opioid receptors and legal highs: *Salvia divinorum* and Kratom. *Clin Toxicol* 2007; 46: 146-152.
83. Preuss H. Report on the Safety of *Caralluma Fimbriata* and its Extract. Georgetown University Medical Center: Washington DC 2004; 1-7.
84. Kuriyan R, Raj T, Srinivas S, Vaz M, Rajendran R, Kurpad A. Effect of *Caralluma fimbriata* extract on appetite, food intake and anthropometry in adult Indian men and women. *Appetite* 2007; 48: 338-344.
85. Kunert O, Rao V, Babu G, Sujatha P, Sivagamy M, Anuradha S, Rao B, Kumar B, Alex R, Schuhly W. Pregnane glycosides from *Caralluma adscendens* var. fimbriata. *Chem. Biodivers* 2008; 5: 239 - 250
86. Kalix P. *Catha edulis*, a plant that has amphetamine effects. *Pharm World Sci* 1996; 18: 69-73.

## References

87. Murray CDR, Le Roux CW, Emmanuel AV, Halket JM, Przyborowska AM, Kamm MA, Murray-Lyon IM. The effect of Khat (*Catha edulis*) as an appetite suppressant is independent of ghrelin and PYY secretion. *Appetite* 2008; 51: 747-750.
88. Heymann T, Buphulan A, Zureikant N, Bomanji J, Drinkwater C, Giles P, Murray-Lyon I. Khat chewing delays gastric emptying of a semi-solid meal. *Aliment Pharmacol Ther* 1995; 9: 81-83.
89. Al-Zubairi A, Al-Habori M, Al-Geiry A. Effect of *Catha edulis* (khat) chewing on plasma lipid peroxidation. *J Ethnopharmacol* 2003; 87: 3-9.
90. Al-Motarreb AL, Broadley KJ. Coronary and aortic vasoconstriction by cathinone, the active constituent of khat. *Auton Autacoid Pharmacol* 2003; 23: 319-326.
91. Yoshioka M, St-Pierre S, Drapeau V, Dionne I, Doucet E, Suzuki M, Tremblay A. Effects of red pepper on appetite and energy intake. *Br J Nutr* 1999; 82: 115-123.
92. Westerterp-Plantenga MS, Smeets A, Lejeune MPG. Sensory and gastrointestinal satiety effects of capsaicin on food intake. *Int J Obes Relat Metab Disord* 2004; 29: 682-688.
93. Lejeune M, Kovacs E, Westerterp-Plantenga M. Effect of capsaicin on substrate oxidation and weight maintenance after modest body-weight loss in human subjects. *Br J Nutr* 2003; 90: 651.
94. Smeets A, Westerterp-Plantenga M. The acute effects of a lunch containing capsaicin on energy and substrate utilisation, hormones, and satiety. *Eur J Nutr* 2009; 48: 229-234.
95. Saito M, Ueno M, Ogino S, Kubo K, Nagata J, Takeuchi M. High dose of *Garcinia cambogia* is effective in suppressing fat accumulation in developing male Zucker obese rats, but highly toxic to the testis. *Food Chem Toxicol* 2005; 43: 411-419.
96. Lewis YS, Neelakantan S. (-)-Hydroxycitric acid-the principal acid in the fruits of *Garcinia cambogia* descr. *Phytochemistry* 1965; 4: 619-625.
97. McCarty MF. Promotion of hepatic lipid oxidation and gluconeogenesis as a strategy for appetite control. *Med Hypotheses* 1994; 42: 215-225.
98. Mattes RD, Bormann L. Effects of (-)-hydroxycitric acid on appetitive variables. *Physiol Behav* 2000; 71: 87-94.
99. Hayamizu K, Hirakawa H, Oikawa D, Nakanishi T, Takagi T, Tachibana T, Furuse M. Effect of *Garcinia cambogia* extract on serum leptin and insulin in mice. *Fitoterapia* 2003; 74: 267-273.
100. Ohia S, Awe S, LeDay A, Opere C, Bagchi D. Effect of hydroxycitric acid on serotonin release from isolated rat brain cortex. *Res Commun Mol Pathol Pharmacol* 2001; 109: 210-216.
101. Ohia SE, Opere CA, LeDay AM, Bagchi M, Bagchi D, Stohs SJ. Safety and mechanism of appetite suppression by a novel hydroxycitric acid extract *Mol Cell Biochem* 2002; 238: 89-103.
102. Hayamizu K, Tomi H, Kaneko I, Shen M, Soni MG, Yoshino G. Effects of *Garcinia cambogia* extract on serum sex hormones in overweight subjects. *Fitoterapia* 2008; 79: 255-261.
103. Burdock G, Bagchi M, Bagchi D. *Garcinia cambogia* toxicity is misleading. *Food Chem Toxicol* 2005; 43: 1683-1684.
104. Butt MS, Shahzadi N, Sharif MK, Nasir M. Guar Gum: A miracle therapy for hypercholesterolemia, hyperglycemia and obesity. *Crit Rev Food Sci Nutr* 2007; 47: 389 - 396.
105. Krotkiewski M. Effect of guar gum on body-weight, hunger ratings and metabolism in obese subjects. *Br J Nutr* 1984; 52: 97-105.
106. Darwiche G, Bjorgell O, Almer L-o. The addition of locust bean gum but not water delayed the gastric emptying rate of a nutrient semisolid meal in healthy subjects. *BMC Gastroenterol* 2003; 3: 12.
107. van Nieuwenhoven MA, Kovacs EMR, Brummer R-JM, Westerterp-Plantenga MS, Brouns F. The effect of different dosages of guar gum on gastric emptying and small intestinal transit of a consumed semisolid meal. *J Am Coll Nutr* 2001; 20: 87-91.
108. Pittler MH, Ernst E. Guar gum for body weight reduction: meta-analysis of randomized trials. *Am J Med* 2001; 110: 724-730.
109. Gonzalez C, Fernandez M, Sahagun A, Garcia V, Diez L, Calle P, Castro R, Sierra V. Glucomannan: properties and therapeutic applications. *Nutr Hosp* 2004; 19: 45-50.
110. Vasques CAR, Rossetto S, Halmenschlager G, Linden R, Heckler E, Fernandez MSP, Alonso JLL. Evaluation of the pharmacotherapeutic efficacy of *Garcinia cambogia* plus *Amorphophallus konjac* for the treatment of obesity. *Phytother Res* 2008; 22: 1135-1140.
111. Chen H-L, Sheu WH-H, Tai T-S, Liaw Y-P, Chen Y-C. Konjac supplement alleviated hypercholesterolemia and hyperglycemia in type 2 diabetic subjects - A randomized double-blind trial. *J Am Coll Nutr* 2003; 22: 36-42.
112. Kim JH, Hahm DH, Yang DC, Kim JH, Lee HJ, Shim I. Effect of crude saponin of Korean red ginseng on high-fat diet induced obesity in the rat. *J Pharmacol Sci* 2005; 97: 124-131.
113. Kim JH, Kang SA, Han S-M, Shim I. Comparison of the antiobesity effects of the protopanaxadiol- and protopanaxatriol-type saponins of red ginseng. *Phytother Res* 2008; 23: 78-85.

114. Hauptman J, Jeunet F, Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin). *Am J Clin Nutr* 1992; 55: 309S-313S.
115. Anderson G, Moore S. Dietary proteins in the regulation of food intake and body weight in humans. *Am Soc Nutrition* 2004; 134: 974.
116. McDougall G, Stewart D. The inhibitory effects of berry polyphenols on digestive enzymes. *Biofactors* 2005; 23: 189-195.
117. Hou W, Li Y, Zhang Q, Wei X, Peng A, Chen L, Wei Y. Triterpene acids isolated from *Lagerstroemia speciosa* leaves as  $\alpha$ -glucosidase inhibitors. *Phytother Res* 2008; 23: 614-618.
118. Park M-Y, Lee K-S, Sung M-K. Effects of dietary mulberry, Korean red ginseng, and banaba on glucose homeostasis in relation to PPAR $\alpha$ , PPAR $\gamma$ , and LPL mRNA expressions. *Life Sci* 2005; 77: 3344-3354.
119. Judy W, Hari S, Stogsdill W, Judy J, Naguib Y, Passwater R. Antidiabetic activity of a standardized extract (Glucosol (TM)) from *Lagerstroemia speciosa* leaves in Type II diabetics: A dose-dependence study. *J Ethnopharmacol* 2003; 87: 115-117.
120. Hansawasdi C, Kawabata J, Kasai T.  $\alpha$ -Amylase Inhibitors from roselle (*Hibiscus sabdariffa* Linn.) tea. *Biosci Biotechnol Biochem* 2000; 64: 1041-1043.
121. Ono Y, Hattori E, Fukaya Y, Imai S, Ohizumi Y. Anti-obesity effect of *Nelumbo nucifera* leaves extract in mice and rats. *J Ethnopharmacol* 2006; 106: 238-244.
122. Marshall J, Lauda C. Purification and properties of phaseolamin, an inhibitor of  $\alpha$ -amylase, from the kidney bean, *Phaseolus vulgaris*. *J Biol Chem* 1975; 250: 8030-8037.
123. Celleno L, Tolaini M, D'Amore A, Perricone N, Preuss H. A dietary supplement containing standardized *Phaseolus vulgaris* extract influences body composition of overweight men and women. *Int J Med Sci* 2007; 4: 45.
124. Birketvedt G, Travis A, Langbakk B, Florholmen J. Dietary supplementation with bean extract improves lipid profile in overweight and obese subjects. *Nutrition* 2002; 18: 729-733.
125. Boniglia C, Carratù B, Di Stefano S, Giammarioli S, Mosca M, Sanzini E. Lectins, trypsin and  $\alpha$ -amylase inhibitors in dietary supplements containing *Phaseolus vulgaris*. *Eur Food Res Technol* 2008; 227: 689-693.
126. Preuss H, Echard B, Bagchi D, Stohs S. Inhibition by natural dietary substances of gastrointestinal absorption of starch and sucrose in rats and pigs: 1. Acute studies. *Int J Med Sci* 2007; 4: 196.
127. Chokshi D. Subchronic oral toxicity of a standardized white kidney bean (*Phaseolus vulgaris*) extract in rats. *Food Chem Toxicol* 2007; 45: 32-40.
128. Hollenbeck C, Coulston A, Quan R, Becker T, Vreman H, Stevenson D, Reaven G. Effects of a commercial starch blocker preparation on carbohydrate digestion and absorption: in vivo and in vitro studies. *Am J Clin Nutr* 1983; 38: 498-503.
129. Carlson G, Li B, Bass P, Olsen W. A bean  $\alpha$ -amylase inhibitor formulation (starch blocker) is ineffective in man. *Science* 1983; 219: 393-395.
130. Fordyce-Baum M, Langer L, Mantero-Atienza E, Crass R, Beach R. Use of an expanded-whole-wheat product in the reduction of body weight and serum lipids in obese females. *Am J Clin Nutr* 1989; 50: 30-36.
131. Choudhury A, Maeda K, Murayama R, DiMaggio E. Character of a wheat amylase inhibitor preparation and effects on fasting human pancreaticobiliary secretions and hormones. *Gastroenterology* 1996; 111: 1313-1320.
132. Oneda H, Lee S, Inouye K. Inhibitory effect of 0.19  $\alpha$ -amylase inhibitor from wheat kernel on the activity of porcine pancreas  $\alpha$ -amylase and its thermal stability. *J Biochem* 2004; 135: 421-427.
133. Oku T, Yamada M, Nakamura M, Sadamori N, Nakamura S. Inhibitory effects of extractives from leaves of *Morus alba* on human and rat small intestinal disaccharidase activity. *Br J Nutr* 2007; 95: 933-938.
134. Andallu B, Suryakantham V, Lakshmi Srikanthi B, Kesava Reddy G. Effect of mulberry (*Morus indica* L.) therapy on plasma and erythrocyte membrane lipids in patients with type 2 diabetes. *Clin Chim Acta* 2001; 314: 47-53.
135. Yatsunami K, Ichida M, Onodera S. The relationship between 1-deoxynojirimycin content and  $\alpha$ -glucosidase inhibitory activity in leaves of 276 mulberry cultivars (*Morus* spp.) in Kyoto, Japan. *J Nat Med* 2008; 62: 63-66.
136. Lee J, Chae K, Ha J, Park B, Lee H, Jeong S, Kim M, Yoon M. Regulation of obesity and lipid disorders by herbal extracts from *Morus alba*, *Melissa officinalis*, and *Artemisia capillaris* in high-fat diet induced obese mice. *J Ethnopharmacol* 2007.
137. Hansawasdi C, Kawabata J.  $\alpha$ -Glucosidase inhibitory effect of mulberry (*Morus alba*) leaves on Caco-2. *Fitoterapia* 2006; 77: 568-573.
138. Dey L, Xie JT, Wang A, Wu J, Maleckar SA, Yuan CS. Anti-hyperglycemic effects of ginseng: Comparison between root and berry. *Phytomedicine* 2003; 10: 600-605.
139. Karu N, Reifern R, Kerem Z. Weight gain reduction in mice fed *Panax ginseng* Saponin, a pancreatic lipase inhibitor. *J Agric Food Chem* 2007; 55: 2824-2828.

## References

140. Xie JT, Zhou YP, Dey L, Attele AS, Wu JA, Gu M, Polonsky KS, Yuan CS. Ginseng berry reduces blood glucose and body weight in db/db mice. *Phytomedicine* 2002; 9: 254-258.
141. Vuksan V, Sung M-K, Sievenpiper JL, Stavro PM, Jenkins AL, Di Buono M, Lee K-S, Leiter LA, Nam KY, Arnason JT, Choi M, Naeem A. Korean red ginseng (*Panax ginseng*) improves glucose and insulin regulation in well-controlled, type 2 diabetes: Results of a randomized, double-blind, placebo-controlled study of efficacy and safety. *Nutr Metab Cardiovasc Dis* 2008; 18: 46-56.
142. Attele A, Zhou Y, Xie J, Wu J, Zhang L, Dey L, Pugh W, Rue P, Polonsky K, Yuan C. Antidiabetic effects of *Panax ginseng* berry extract and the identification of an effective component. *Diabetes* 2002; 51: 1851-1858.
143. Wu Z, Luo J, Luo L. American ginseng modulates pancreatic beta cell activities. *Chin Med* 2007; 2: 11.
144. Liu W, Zheng Y, Han L, Wang H, Saito M, Ling M, Kimura Y, Feng Y. Saponins (Ginsenosides) from stems and leaves of *Panax quinquefolium* prevented high-fat diet-induced obesity in mice. *Phytomedicine* 2008; 15: 1140-1145.
145. Vuksan V, Stavro M, Sievenpiper J, Beljan-Zdravkovic U, Leiter L, Josse R, Xu Z. Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes. *Diabetes Care* 2000; 23: 1221-1226.
146. Vuksan V, Stavro M, Sievenpiper J, Koo V, Wong E, Beljan-Zdravkovic U, Francis T, Jenkins A, Leiter L, Josse R. American ginseng improves glycemia in individuals with normal glucose tolerance: effect of dose and time escalation. *J Am Coll Nutr* 2000; 19: 738-744.
147. Ekanem AP, Wang M, Simon JE, Moreno DA. Antiobesity properties of two African plants (*Aframomum meleguetta* and *Spilanthes acmella*) by pancreatic lipase inhibition. *Phytother Res* 2007; 21: 1253-1255.
148. Han L-K, Sumiyoshi M, Zhang J, Liu M-X, Zhang X-F, Zheng Y-N, Okuda H, Kimura Y. Anti-obesity action of *Salix matsudana* leaves (Part 1). Anti-obesity action by polyphenols of *Salix matsudana* in high fat-diet treated rodent animals. *Phytother Res* 2003; 17: 1188-1194.
149. Han L-K, Sumiyoshi M, Zheng Y-N, Okuda H, Kimura Y. Anti-obesity action of *Salix matsudana* leaves (Part 2). Isolation of anti-obesity effectors from polyphenol fractions of *Salix matsudana*. *Phytother Res* 2003; 17: 1195-1198.
150. Won S-R, Kim S-K, Kim Y-M, Lee P-H, Ryu J-H, Kim J-W, Rhee H-I. Licochalcone A: A lipase inhibitor from the roots of *Glycyrrhiza uralensis*. *Food Res Int* 2007; 40: 1046-1050.
151. Lei F, Zhang XN, Wang W, Xing DM, Xie WD, Su H, Du LJ. Evidence of anti-obesity effects of the pomegranate leaf extract in high-fat diet induced obese mice. *Int J Obes* 2007; 31: 1023-1029.
152. Morrison R, Farmer S. Insights into the transcriptional control of adipocyte differentiation. *J Cell Biochem* 1999; 59-67.
153. Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, Satoh S, Nakano R, Ishii C, Sugiyama T. PPAR $\gamma$  mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. *Mol Cell* 1999; 4: 597-609.
154. Rosen E, MacDougald O. Adipocyte differentiation from the inside out. *Nature Rev Mol Cell Biol* 2006; 7: 885-896.
155. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM. The nuclear receptor superfamily: The second decade. *Cell* 1995; 83: 835-839.
156. Chawla A, Schwarz E, Dimaculangan D, Lazar M. Peroxisome proliferator-activated receptor (PPAR)  $\gamma$ : adipose predominant expression and induction early in adipocyte differentiation. *Endocrinology* 1994; 135: 798-800.
157. Rosen E, Walkey C, Puigserver P, Spiegelman B. Transcriptional regulation of adipogenesis. *Genes & Dev* 2000; 14: 1293-1307.
158. Kim M, Kim J, Kim H, Moon S, Shin B, Park K, Yang H, Kim S, Park R. *Hibiscus* extract inhibits the lipid droplet accumulation and adipogenic transcription factors expression of 3T3-L1 preadipocytes. *J Altern Complement Med* 2003; 9: 499-504.
159. Alarcon-Aguilar FJ, Zamilpa A, Perez-Garcia MD, Almanza-Perez JC, Romero-Núñez E, Campos-Sepulveda EA, Vazquez-Carrillo LI, Roman-Ramos R. Effect of *Hibiscus sabdariffa* on obesity in MSG mice. *J Ethnopharmacol* 2007; 114: 66-71.
160. Lalmoddin Mollah M, Kim G-S, Moon H-K, Chung S-K, Cheon Y-P, Kim J-K, Kim K-S. Antiobesity effects of wild ginseng (*Panax ginseng* C.A. Meyer) mediated by PPAR $\gamma$ , GLUT4 and LPL in ob/ob mice. *Phytother Res* 2009; 23: 220-225.
161. Yun S, Moon S, Ko S, Im B, Chung S. Wild ginseng prevents the onset of high-fat diet induced hyperglycemia and obesity in ICR mice. *Arch Pharm Res* 2004; 27: 790-796.

162. Hwang J, Kim S, Lee M, Yang H, Kim M, Kim H, Ha J, Kim M, Kwon D. Anti-obesity effects of ginsenoside Rh2 are associated with the activation of AMPK signaling pathway in 3T3-L1 adipocyte. *Biochem Biophys Res Commun* 2007; 364 (4): 1002-1008.
163. Park S, Ahn IS, Kwon DY, Ko BS, Jun WK. Ginsenosides Rb1 and Rg1 suppress triglyceride accumulation in 3T3-L1 adipocytes and enhance beta-cell insulin secretion and viability in Min6 cells via PKA-dependent pathways. *Biosci Biotechnol Biochem* 2008; 72: 2815-2823.
164. Ninomiya K, Matsuda H, Kubo M, Morikawa T, Nishida N, Yoshikawa M. Potent anti-obese principle from *Rosa canina*: Structural requirements and mode of action of trans-tiliroside. *Bioorg Med Chem Lett* 2007; 17: 3059-3064.
165. Jeon J-R, Kim J-Y. Effects of pine needle extract on differentiation of 3T3-L1 preadipocytes and obesity in high-fat diet fed rats. *Biol Pharm Bull* 2006; 29: 2111-2115.
166. Dulloo AG, Duret C, Rohrer D, Girardier L, Mensi N, Fathi M, Chantre P, Vandermander J. Efficacy of a green tea extract rich in catechin polyphenols and caffeine in increasing 24-h energy expenditure and fat oxidation in humans. *Am J Clin Nutr* 1999; 70: 1040-1045.
167. Juhel C, Armand M, Pafumi Y, Rosier C, Vandermander J, Lairon D. Green tea extract (AR25®) inhibits lipolysis of triglycerides in gastric and duodenal medium in vitro. *J Nutr Biochem* 2000; 11: 45-51.
168. Chantre P, Lairon D. Recent findings of green tea extract AR25 (Exolise) and its activity for the treatment of obesity. *Phytomedicine* 2002; 9: 3-8.
169. Kao Y-H, Hiiipakka RA, Liao S. Modulation of endocrine systems and food intake by green tea epigallocatechin gallate. *Endocrinology* 2000; 141: 980-987.
170. Ashida H. Anti-obesity actions of green tea: possible involvements in modulation of the glucose uptake system and suppression of the adipogenesis-related transcription factors. *Biofactors* 2004; 22: 135-140.
171. Klaus S, Pultz S, Thone-Reineke C, Wolfram S. Epigallocatechin gallate attenuates diet-induced obesity in mice by decreasing energy absorption and increasing fat oxidation. *Int J Obes Relat Metab Disord* 2005; 29: 615-623.
172. Yeh Y-Y, Leveille GA, Wiley JH. Influence of dietary lipid on lipogenesis and on the activity of malic enzyme and citrate cleavage enzyme in liver of the growing chick. *J Nutr* 1970; 100: 917-924.
173. Kovacs E, Lejeune M, Nijs I, Westerterp-Plantenga M. Effects of green tea on weight maintenance after body-weight loss. *Br J Nutr* 2007; 91: 431-437.
174. Wolfram S, Wang Y, Thielecke F. Anti-obesity effects of green tea: from bedside to bench. *Mol Nutr Food Res* 2006; 50(2): 176-187.
175. Cook CB, Nair R, Herminghuysen D, Gatchair-Rose A, Rao J, Bagby GJ, Prasad C. Epididymal fat depot lipoprotein lipase activity is lower in animals with high endogenous fat preferences. *Life Sci* 1995; 57: 839-845.
176. Iwashita K, Yamaki K, Tshushida T. Mioga (*Zingiber mioga* Rosc.) extract prevents 3T3-L1 differentiation into adipocytes and obesity in mice. *Food Sci Technol Res* 2001; 7: 164-170.
177. Gracie AJ, Brown PH, Burgess SW, Clark RJ. Rhizome dormancy and shoot growth in myoga (*Zingiber mioga* Roscoe). *Sci Hort* 2000; 84: 27-36.
178. Bhandari U, Sharma JN, Zafar R. The protective action of ethanolic ginger (*Zingiber officinale*) extract in cholesterol fed rabbits. *J Ethnopharmacol* 1998; 61: 167-171.
179. Bhandari U, kanojia R, Pillai KK. Effect of ethanolic extract of *Zingiber officinale* on dyslipidaemia in diabetic rats. *J Ethnopharmacol* 2005; 97: 227-230.
180. Al-Amin Z, Thomson M, Al-Qattan K, Peltonen-Shalaby R, Ali M. Anti-diabetic and hypolipidaemic properties of ginger (*Zingiber officinale*) in streptozotocin-induced diabetic rats. *Brit J Nutr* 2007; 96: 660-666.
181. Han L-K, Gong X-J, Kawano S, Saito M, Kimura Y, Okuda H. Antiobesity actions of *Zingiber officinale* Roscoe. *Yakugaku Zasshi* 2005; 125: 213-217.
182. Ojewole JAO. Analgesic, antiinflammatory and hypoglycaemic effects of ethanol extract of *Zingiber officinale* (roscoe) rhizomes (*Zingiberaceae*) in mice and rats. *Phytother Res* 2006; 20: 764-772.
183. Isa Y, Miyakawa Y, Yanagisawa M, Goto T, Kang M-S, Kawada T, Morimitsu Y, Kubota K, Tsuda T. 6-Shogaol and 6-gingerol, the pungent of ginger, inhibit TNF-[alpha] mediated downregulation of adiponectin expression via different mechanisms in 3T3-L1 adipocytes. *Biochem Biophys Res Commun* 2008; 373: 429-434.
184. Kim SO, Yun S-J, Jung B, Lee EH, Hahm D-H, Shim I, Lee H-J. Hypolipidemic effects of crude extract of adlay seed (*Coix lachrymajobi* var. mayuen) in obesity rat fed high fat diet : Relations of TNF $\alpha$  and leptin mRNA expressions and serum lipid levels. *Life Sci* 2004; 75: 1391-1404.
185. Liu F, Kim J-K, Li Y, Liu X-q, Li J, Chen X. An extract of *Lagerstroemia speciosa* L. Has Insulin-like glucose uptake-stimulatory and adipocyte differentiation-inhibitory activities in 3T3-L1 cells. *J Nutr* 2001; 131: 2242-2247.



## References

186. Hayashi T, Maruyama H, Kasai R, Hattori K, Takasuga S, Hazeki O, Yamasaki K, Tanaka T. Ellagitannins from *Lagerstroemia speciosa* as activators of glucose transport in fat cells. *Planta Med* 2002; 68: 173-175.
187. Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. *Cell* 2001; 104: 531-543.
188. Walters WP, Namchuk M. Designing screens: how to make your hits a hit. *Nat Rev Drug Discov* 2003; 2: 259-266.
189. Arner P. Human fat cell lipolysis: Biochemistry, regulation and clinical role. *Best Pract Res Clin En* 2005; 19: 471-482.
190. Langin D. Adipose tissue lipolysis as a metabolic pathway to define pharmacological strategies against obesity and the metabolic syndrome. *Pharmacol Res* 2006; 53: 482-491.
191. Sengenès C, Berlan M, De Glisezinski I, Lafontan M, Galitzky J. Natriuretic peptides: a new lipolytic pathway in human adipocytes. *FASEB J* 2000; 14: 1345-1351.
192. Fernandez C, Hansson O, Nevsten P, Holm C, Klint C. Hormone-sensitive lipase is necessary for normal mobilization of lipids during submaximal exercise. *Am J Physiol Endocrinol Metab* 2008; 295: E179-186.
193. Zimmermann R, Strauss JG, Haemmerle G, Schoiswohl G, Birner-Gruenberger R, Riederer M, Lass A, Neuberger G, Eisenhaber F, Hermetter A, Zechner R. Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. *Science* 2004; 306: 1383-1386.
194. Soni KG, Lehner R, Metalnikov P, O'Donnell P, Semache M, Gao W, Ashman K, Pshezhetsky AV, Mitchell GA. Carboxylesterase 3 (EC 3.1.1.1) is a major adipocyte lipase. *J Biol Chem* 2004; 279: 40683-40689.
195. Yeaman S. Hormone-sensitive lipase-new roles for an old enzyme. *Biochem J* 2004; 379: 11-22.
196. Syu L-J, Saltiel AR. Lipotransin: A novel docking protein for hormone-sensitive lipase. *Mol Cell* 1999; 4: 109-115.
197. Sztalryd C, Xu G, Dorward H, Tansey JT, Contreras JA, Kimmel AR, Londos C. Perilipin A is essential for the translocation of hormone-sensitive lipase during lipolytic activation. *J Cell Biol* 2003; 161: 1093-1103.
198. Winder WW, Hardie DG. AMP-activated protein kinase, a metabolic master switch: possible roles in Type 2 diabetes. *Am J Physiol Endocrinol Metab* 1999; 277: E1-10.
199. Hardie DG, Carling D, Carlson M. The AMP-activated / SNF1 protein kinase subfamily: Metabolic sensors of the eukaryotic cell? *Annu Rev Biochem* 1998; 67: 821-855.
200. Arch JRS, Ainsworth AT, Cawthorne MA, Piercy V, Sennitt MV, Thody VE, Wilson C, Wilson S. Atypical beta-adrenoceptor on brown adipocytes as target for anti-obesity drugs. *Nature* 1984; 309: 163-165.
201. Lowell BB, Flier JS. Brown adipose tissue, beta-3 adrenergic receptors, and obesity. *Annu Rev Med* 1997; 48: 307-316.
202. Arch J. The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from beta-3 adrenoceptor agonists. *Naunyn Schmiedebergs Arch Pharmacol* 2008; 378: 225-240.
203. Ghorbani M, Claus TH, Himms-Hagen J. Hypertrophy of brown adipocytes in brown and white adipose tissues and reversal of diet-induced obesity in rats treated with a [beta]3-adrenoceptor agonist. *Biochem Pharmacol* 1997; 54: 121-131.
204. Granneman J, Lahners K. Analysis of human and rodent beta 3-adrenergic receptor messenger ribonucleic acids. *Endocrinology* 1994; 135: 1025-1031.
205. Lean MEJ. Brown adipose tissue in humans. *Proc Nutr Soc* 1989; 48: 243-257.
206. Nedergaard J, Bengtsson T, Cannon B. Unexpected evidence for active brown adipose tissue in adult humans. *Am J Physiol Endocrinol Metab* 2007; 293: E444.
207. Saito M, Okamatsu-Ogura Y, Matsushita M, Watanabe K, Yoneshiro T, Nio-Kobayashi J, Iwanaga T, Miyagawa M, Kameya T, Nakada K. High incidence of metabolically active brown adipose tissue in healthy adult humans. *Diabetes* 2009; 58: 1526.
208. Cypess AM, Lehman S, Williams G, Tal I, Rodman D, Goldfine AB, Kuo FC, Palmer EL, Tseng Y-H, Doria A, Kolodny GM, Kahn CR. Identification and importance of brown adipose tissue in adult humans. *N Engl J Med* 2009; 360: 1509-1517.
209. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1[alpha]. *Cell* 2006; 127: 1109-1122.
210. Rayalam S, Yang J-Y, Ambati S, Della-Fera MA, Baile CA. Resveratrol induces apoptosis and inhibits adipogenesis in 3T3-L1 adipocytes. *Phytother Res* 2008; 22: 1367-1371.
211. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA. Resveratrol improves health and survival of mice on a high-calorie diet. *Nature* 2006; 444: 337-342.

212. Wang Y, Catana F, Yang Y, Roderick R, van Breemen RB. An LC-MS method for analyzing total resveratrol in grape juice, cranberry juice, and in wine. *J Agric Food Chem* 2002; 50: 431-435.
213. van der Spuy WJ, Pretorius E. Is the use of resveratrol in the treatment and prevention of obesity premature? *Nutrition Research Reviews* 2009; 22: 111-117.
214. Ardevol A, Blade C, Salvado M, Arola L. Changes in lipolysis and hormone-sensitive lipase expression caused by procyanidins in 3T3-L1 adipocytes. *Int J Obes* 2000; 24: 319-324.
215. Pinent M, Blade M, Cinta, Salvado MJ, Arola L, Ardevol A. Intracellular mediators of procyanidin-induced lipolysis in 3T3-L1 adipocytes. *J Agric Food Chem* 2005; 53: 262-266.
216. Pinent M, Blade M, Salvado M, Arola L, Hackl H, Quackenbush J, Trajanoski Z, Ardevol A. Grape-seed derived procyanidins interfere with adipogenesis of 3T3-L1 cells at the onset of differentiation. *Int J Obes* 2005; 29: 934-941.
217. Kim S-h, Park H-S, Lee M-s, Cho Y-J, Kim Y-S, Hwang J-T, Sung MJ, Kim MS, Kwon DY. Vitisin A inhibits adipocyte differentiation through cell cycle arrest in 3T3-L1 cells. *Biochem Biophys Res Commun* 2008; 372: 108-113.
218. Vogels N, Nijs I, Westerterp-Plantenga M. The effect of grape-seed extract on 24 h energy intake in humans. *Eur J Clin Nutr* 2004; 58: 667-673.
219. Hollis J, Houchins J, Blumberg J, Mattes R. Effects of concord grape juice on appetite, diet, body weight, lipid profile, and antioxidant status of adults. *J Am Coll Nutr* 2009; 28: 574-582.
220. Flechtner-Mors M, Biesalski HK, Jenkinson CP, Adler G, Ditschuneit HH. Effects of moderate consumption of white wine on weight loss in overweight and obese subjects. *Int J Obes Relat Metab Disord* 2004; 28: 1420-1426.
221. Fujioka K, Greenway F, Sheard J, Ying Y. The effects of grapefruit on weight and insulin resistance: Relationship to the metabolic syndrome. *J Med Food* 2006; 9: 49-54.
222. Dallas C, Gerbi A, Tenca G, Juchaux F, Bernard F. Lipolytic effect of a polyphenolic citrus dry extract of red orange, grapefruit, orange (SINETROL) in human body fat adipocytes. Mechanism of action by inhibition of cAMP-phosphodiesterase (PDE). *Phytomedicine* 2008; 15: 783-792.
223. Penzak S. Seville (2) orange juice: synephrine content and cardiovascular effects in normotensive adults. *J Clin Pharmacol* 2001; 41: 1059-1063.
224. Airriess CN, Rudling JE, Midgley JM, Evans PD. Selective inhibition of adenylyl cyclase by octopamine via a human cloned  $\alpha_{2A}$ -adrenoceptor. *Br J Pharmacol* 1997; 122: 191-198.
225. Carpéné C, Galitzky J, Fontana E, Atgié C, Lafontan M, Berlan M. Selective activation of  $\beta_3$ -adrenoceptors by octopamine: comparative studies in mammalian fat cells. *Naunyn Schmiedebergs Arch Pharmacol* 1999; 359: 310-321.
226. Fugh-Berman A, Myers A. Citrus aurantium, an ingredient of dietary supplements marketed for weight loss: Current status of clinical and basic research. *Exp Biol Med* 2004; 229: 698-704.
227. Gougeon R, Harrigan K, Tremblay J-F, Hedrei P, Lamarche M, Morais JA. Increase in the thermic effect of food in women by adrenergic amines extracted from *Citrus aurantium*. *Obesity* 2005; 13: 1187-1194.
228. Calapai G, Firenzuoli F, Saitta A, Squadrito F, R. Arlotta M, Costantino G, Inferra G. Antiobesity and cardiovascular toxic effects of *Citrus aurantium* extracts in the rat: a preliminary report. *Fitoterapia* 1999; 70: 586-592.
229. Firenzuoli F, Gori L, Galapai C. Adverse reaction to an adrenergic herbal extract (*Citrus aurantium*). *Phytomedicine* 2005; 12: 247-248.
230. Bent S, Padula A, Neuhaus J. Safety and efficacy of *Citrus aurantium* for weight loss. *Am J Cardiol* 2004; 94: 1359-1361.
231. Pellati F, Benvenuti S, Melegari M. High-performance liquid chromatography methods for the analysis of adrenergic amines and flavanones in *Citrus aurantium* L. var. *amara*. *Phytochem Anal* 2004; 15: 220-225.
232. Haaz S, Fontaine KR, Cutter G, Limdi N, Perumean-Chaney S, Allison DB. *Citrus aurantium* and synephrine alkaloids in the treatment of overweight and obesity: an update. *Obes Rev* 2006; 7: 79-88.
233. Louw V. *Citrus aurantium*, beware of the bitter orange. *S Afr Med J* 2008; 98: 496.
234. Ji X, Tan B, Zhu Y. *Salvia miltiorrhiza* and ischemic diseases. *Acta Pharmacol Sin* 2000; 21: 1089-1094.
235. Kim EJ, Jung S-N, Son KH, Kim SR, Ha TY, Park MG, Jo IG, Park JG, Choe W, Kim S-S, Ha J. Antidiabetes and antiobesity effect of cryptotanshinone via activation of AMP-activated protein kinase. *Mol Pharmacol* 2007; 72: 62-72.
236. Smith SJ, Cases S, Jensen DR, Chen HC, Sande E, Tow B, Sanan DA, Raber J, Eckel RH, Farese RV. Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat. *Nat Genet* 2000; 25: 87-90.
237. Ko J, Ryu S, Kim Y, Chung M, Kang J, Rho M-C, Lee H. Inhibitory activity of diacylglycerol acyltransferase by tanshinones from the root of *Salvia miltiorrhiza*. *Arch Pharm Res* 2002; 25: 446-448.
238. Lin C-L, Huang H-C, Lin J-K. Theaflavins attenuate hepatic lipid accumulation through activating AMPK in human HepG2 cells. *J Lipid Res* 2007; 48: 2334-2343.

## References

239. Han L, Takaku T, Li J, Kimura Y, Okuda H. Anti-obesity action of Oolong tea. *Int J Obes* 1999; 23: 98-105.
240. Choo JJ. Green tea reduces body fat accretion caused by high-fat diet in rats through  $\beta$ -adrenoceptor activation of thermogenesis in brown adipose tissue. *J Nutr Biochem* 2003; 14: 671-676.
241. Rains TM, Agarwal S, Maki KC. Antiobesity effects of green tea catechins: a mechanistic review. *J Nutr Biochem* 2011; 22: 1-7.
242. Khan N, Mukhtar H. Tea polyphenols for health promotion. *Life Sci* 2007; 81: 519-533.
243. Rumpel W, Seale J, Clevidence B, Judd J, Wiley E, Yamamoto S, Komatsu T, Sawaki T, Ishikura Y, Hosoda K. Oolong tea increases metabolic rate and fat oxidation in men. *J Nutr* 2001; 131: 2848-2852.
244. Boschmann M, Thielecke F. The effects of epigallocatechin-3-gallate on thermogenesis and fat oxidation in obese men: a pilot study. *J Am Coll Nutr* 2007; 26: 389S-395.
245. Dulloo A, Seydoux J, Girardier L, Chantre P, Vandermander J. Green tea and thermogenesis: interactions between catechin-polyphenols, caffeine and sympathetic activity. *Int J Obes* 2000; 24: 252-258.
246. Westerterp-Plantenga MS, Lejeune MP, Kovacs EM. Body weight loss and weight maintenance in relation to habitual caffeine intake and green tea supplementation. *Obesity* 2005; 13: 1195-1204.
247. Lemaure B, Touché A, Zbinden I, Courtois D, Macé K, Darimont C. Administration of *Cyperus rotundus* tubers extract prevents weight gain in obese Zucker rats. *Phytother Res* 2007; 21: 724-730.
248. Loh HH, Law PY. The role of membrane lipids in receptor mechanisms. *Annu Rev Pharmacol Toxicol* 1980; 20: 201-234.
249. Ingkaninan K, von Frijtag Drabbe Kunzel JK, Ijzerman AP, Verpoorte R. Interference of linoleic acid fraction in some receptor binding assays. *J Nat Prod* 1999; 62: 912-914.
250. Maeda H, Hosokawa M, Sashima T, Funayama K, Miyashita K. Fucoxanthin from edible seaweed, *Undaria pinnatifida*, shows antiobesity effect through UCP1 expression in white adipose tissues. *Biochem Biophys Res Commun* 2005; 332: 392-397.
251. Abidov M, Ramazanov Z, Seifulla R, Grachev S. The effects of Xanthigen™ in the weight management of obese premenopausal women with non-alcoholic fatty liver disease and normal liver fat. *Diabetes Obes Metab* 2010; 12: 72-81.
252. Teas J, Baldeon M, Chiriboga D, Davis J, Sarriés A, Braverman L. Could dietary seaweed reverse the metabolic syndrome? *Asia Pac J Clin Nutr* 2009; 18: 145-147.
253. Beppu F, Niwano Y, Tsukui T, Hosokawa M, Miyashita K. Single and repeated oral dose toxicity study of fucoxanthin(3), a marine carotenoid, in mice. *J Toxicol Sci* 2009; 34: 501-510.
254. Messina MJ, Persky V, Setchell KDR, Barnes S. Soy intake and cancer risk: A review of the *in-vitro* and *in-vivo* data. *Nutr Cancer* 1994; 21: 113 - 131.
255. Moriyama T, Kishimoto K, Nagai K, Urade R, Ogawa T, Utsumi S, Maruyama N, Maebuchi M. Soybean beta-Conglycinin diet suppresses serum triglyceride levels in normal and genetically obese mice by induction of beta-oxidation, downregulation of fatty acid synthase, and inhibition of triglyceride absorption. *Biosci Biotechnol Biochem* 2004; 68: 352-359.
256. Nagasawa A, Fukui K, Funahashi T, Maeda N, Shimomura I, Kihara S, Waki M, Takamatsu K, Matsuzawa Y. Effects of soy protein diet on the expression of adipose genes and plasma adiponectin. *Horm Metab Res* 2002; 34: 635-639.
257. Ae Park S, Choi M-S, Cho S-Y, Seo J-S, Jung UJ, Kim M-J, Sung M-K, Park YB, Lee M-K. Genistein and daidzein modulate hepatic glucose and lipid regulating enzyme activities in C57BL/KsJ-db/db mice. *Life Sci* 2006; 79: 1207-1213.
258. Schryver T, Smith C, Wall M. Self-identities and BMI of Minnesotan soy consumers and non-consumers. *Obesity* 2007; 15: 1101-1106.
259. Deibert P, König D, Schmidt-Trucksass A, Zaenker KS, Frey I, Landmann U, Berg A. Weight loss without losing muscle mass in pre-obese and obese subjects induced by a high-soy-protein diet. *Int J Obes Relat Metab Disord* 2004; 28: 1349-1352.
260. Allison DB, Gadbury G, Schwartz LG, Murugesan R, Kraker JL, Heshka S, Fontaine KR, Heymsfield SB. A novel soy-based meal replacement formula for weight loss among obese individuals: a randomized controlled clinical trial. *Eur J Clin Nutr* 2003; 57: 514-522.
261. Li Z, Hong K, Saltsman P, DeShields S, Bellman M, Thames G, Liu Y, Wang HJ, Elashoff R, Heber D. Long-term efficacy of soy-based meal replacements vs an individualized diet plan in obese type II DM patients: relative effects on weight loss, metabolic parameters, and C-reactive protein. *Eur J Clin Nutr* 2004; 59: 411-418.
262. Velasquez M, Bhatena S. Role of dietary soy protein in obesity. *Int. J. Med. Sci.* 2007; 4: 72-82.
263. Aoki F, Honda S, Kishida H, Kitano M, Arai N, Tanaka H, Yokota S, Nakagawa K, Asakura T, Nakai Y, Mae T. Suppression by licorice flavonoids of abdominal fat accumulation and body weight gain in high-fat diet induced obese C57BL/6J mice. *Biosci Biotechnol Biochem* 2007; 71: 206-214.

264. Choi J, Choi J, Lee S, Kim K, Kim Y. Inhibitory activity of diacylglycerol acyltransferase by glabrol isolated from the roots of licorice. *Arch Pharm Res* 2010; 33: 237-242.
265. Tominaga Y, Nakagawa K, Mae T, Kitano M, Yokota S, Arai T, Ikematsu H, Inoue S. Licorice flavonoid oil reduces total body fat and visceral fat in overweight subjects: A randomized, double-blind, placebo-controlled study. *Obes Res Clin Pract* 2009; 3: 169-178.
266. Aoki F, Nakagawa K, Kitano M, Ikematsu H, Nakamura K, Yokota S, Tominaga Y, Arai N, Mae T. Clinical safety of licorice flavonoid oil (LFO) and pharmacokinetics of glabridin in healthy humans. *J Am Coll Nutr* 2007; 26: 209-218.
267. Watanabe T, Kawada T, Yamamoto M, Iwai K. Capsaicin, a pungent principle of hot red pepper, evokes catecholamine secretion from the adrenal medulla of anesthetized rats. *Biochem Biophys Res Commun* 1987; 142: 259-264.
268. Kawada T, Watanabe T, Takaishi T, Tanaka T, Iwai K. Capsaicin-induced beta-adrenergic action on energy metabolism in rats: influence of capsaicin on oxygen consumption, the respiratory quotient, and substrate utilization. *Proceeding of Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine* New York, NY 1986; 250-256.
269. Kawabata F, Inoue N, Yazawa S, Kawada T, Inoue K, Fushiki T. Effects of CH-19 sweet, a non-pungent cultivar of red pepper, in decreasing the body weight and suppressing body fat accumulation by sympathetic nerve activation in humans. *Biosci Biotechnol Biochem* 2006; 70: 2824-2835.
270. Masuda Y, Haramizu S, Oki K, Ohnuki K, Watanabe T, Yazawa S, Kawada T, Hashizume S-i, Fushiki T. Upregulation of uncoupling proteins by oral administration of capsiate, a nonpungent capsaicin analog. *J Appl Physiol* 2003; 95: 2408-2415.
271. Snitker S, Fujishima Y, Shen H, Ott S, Pi-Sunyer X, Furuhashi Y, Sato H, Takahashi M. Effects of novel capsinoid treatment on fatness and energy metabolism in humans: possible pharmacogenetic implications. *Am J Clin Nutr* 2009; 89: 45-50.
272. Morimoto C, Satoh Y, Hara M, Inoue S, Tsujita T, Okuda H. Anti-obese action of raspberry ketone. *Life Sci* 2005; 77: 194-204.
273. Kobayashi Y, Nakano Y, Kizaki M, Hoshikuma K, Yokoo Y, Kamiya T. Capsaicin-like anti-obese activities of evodiamine from fruits of *Evodia rutaecarpa*, a vanilloid receptor agonist. *Planta Med* 2001; 67: 628-633.
274. Kim H-J, Park J-M, Kim J-A, Ko B-P. Effect of herbal *Ephedra sinica* and *Evodia rutaecarpa* on body composition and resting metabolic rate: a randomized, double-blind clinical trial in Korean premenopausal women. *J Acupunct Meridian Stud* 2008; 1: 128-138.
275. Ohkoshi E, Miyazaki H, Shindo K, Watanabe H, Yoshida A, Yajima H. Constituents from the leaves of *Nelumbo nucifera* stimulate lipolysis in the white adipose tissue of mice. *Planta Med* 2007; 73: 1255-1259.
276. Yoon SS, Rhee YH, Lee HJ, Lee EO, Lee MH, Ahn KS, Lim HT, Kim SH. Uncoupled protein 3 and p38 signal pathways are involved in anti-obesity activity of *Solanum tuberosum* L. cv. Bora Valley. *J Ethnopharmacol* 2008; 118: 396-404.
277. Astrup A, Toubro S, Cannon S, Hein P, Breum L, Madsen J. Caffeine: a double-blind, placebo-controlled study of its thermogenic, metabolic, and cardiovascular effects in healthy volunteers. *Am J Clin Nutr* 1990; 51: 759-767.
278. Acheson KJ, Zahorska-Markiewicz B, Pittet P, Anantharaman K, Jequier E. Caffeine and coffee: their influence on metabolic rate and substrate utilization in normal weight and obese individuals. *Am J Clin Nutr* 1980; 33: 989-997.
279. Dulloo AG, Geissler CA, Horton T, Collins A, Miller DS. Normal caffeine consumption: influence on thermogenesis and daily energy expenditure in lean and postobese human volunteers. *Am J Clin Nutr* 1989; 49: 44-50.
280. Lopez-Garcia E, van Dam RM, Rajpathak S, Willett WC, Manson JE, Hu FB. Changes in caffeine intake and long-term weight change in men and women. *Am J Clin Nutr* 2006; 83: 674-680.
281. Vogler BK, Pittler MH, Ernst E. The efficacy of ginseng. A systematic review of randomised clinical trials. *Eur J Clin Pharmacol* 1999; 55: 567-575.
282. Allison DB, Gadbury G, Schwartz LG, Murugesan R, Kraker JL, Heshka S, Fontaine KR, Heymsfield SB. A novel soy-based meal replacement formula for weight loss among obese individuals: a randomized controlled clinical trial. *Eur J Clin Nutr* 2003; 57: 514-522.
283. Fabricant D, Farnsworth N. The value of plants used in traditional medicine for drug discovery. *Environ Health Perspect* 2001; 109: 69-75.
284. Tapsell L, Hemphill I, Cobiack L, Patch C, Sullivan D, Fenech M, Roodenrys S, Keogh J, Clifton P, Williams P. Health benefits of herbs and spices: the past, the present, the future. *Med J Aust* 2006; 185: S4-S24.

## References

285. Aggarwal BB, Van Kuiken ME, Iyer LH, Harikumar KB, Sung B. Molecular targets of nutraceuticals derived from dietary spices: Potential role in suppression of inflammation and tumorigenesis. *Exp Biol Med* 2009; 234: 825-849.
286. Ortega R. Importance of functional foods in the Mediterranean diet. *Public Health Nutr* 2006; 9: 1136-1140.
287. Ninfali P, Mea G, Giorgini S, Rocchi M, Bacchiocca M. Antioxidant capacity of vegetables, spices and dressings relevant to nutrition. *Br J Nutr* 2007; 93: 257-266.
288. Yu L, Shirai N, Suzuki H. Effects of some Chinese spices on body weights, plasma lipids, lipid peroxides, and glucose, and liver lipids in mice. *Food Sci Technol Res* 2007; 13: 155-161.
289. Woo H-M, Kang J-H, Kawada T, Yoo H, Sung M-K, Yu R. Active spice-derived components can inhibit inflammatory responses of adipose tissue in obesity by suppressing inflammatory actions of macrophages and release of monocyte chemoattractant protein-1 from adipocytes. *Life Sci* 2007; 80: 926-931.
290. Chang L, Brussee J, IJzerman A. Non-xanthine antagonists for the adenosine A<sub>1</sub> receptor. *Chem Biodiv* 2004; 1: 1591-1626.
291. Dalpiaz A, Townsend-Nicholson A, Beukers MW, Schofield PR, IJzerman AP. Thermodynamics of full agonist, partial agonist, and antagonist binding to wild-type and mutant adenosine A<sub>1</sub> receptors. *Biochem Pharmacol* 1998; 56: 1437-1445.
292. Ross R, Brockie H, Stevenson L, Murphy V, Templeton F, Makriyannis A, Pertwee R. Agonist-inverse agonist characterization at CB<sub>1</sub> and CB<sub>2</sub> cannabinoid receptors of L759633, L759656 and AM630. *Br J Pharmacol* 1999; 126: 665-672.
293. Sundstrom C, Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). *Int J Cancer* 1976; 17: 565-577.
294. Cho J, Kim P, Park J, Yoo E, Baik K, Kim Y, Park M. Inhibitor of tumor necrosis factor- production in lipopolysaccharide-stimulated RAW264. 7 cells from *Amorpha fruticosa*. *J Ethnopharmacol* 2000; 70: 127-133.
295. Ide T, Ashakumary L, Takahashi Y, Kushihiro M, Fukuda N, Sugano M. Sesamin, a sesame lignan, decreases fatty acid synthesis in rat liver accompanying the down-regulation of sterol regulatory element binding protein-1. *BBA-Mol Cell Biol Lipids* 2001; 1534: 1-13.
296. Ryan E, Galvin K, O'Connor T, Maguire A, O'Brien N. Phytosterol, squalene, tocopherol content and fatty acid profile of selected seeds, grains, and legumes. *Plant Foods Hum Nutr* 2007; 62: 85-91.
297. Malterud K, Hanche-Olsen I, Smith-Kielland I. Flavonoids from *Orthosiphon spicatus*. *Planta Med* 1989; 55: 569-570.
298. Wollenweber E, Mann K. Further flavonoids from *Orthosiphon spicatus*. *Planta Med* 1985; 51: 459-460.
299. Awale S, Tezuka Y, Banskota AH, Kadota S. Inhibition of NO production by highly-oxygenated diterpenes of *Orthosiphon stamineus* and their structure activity relationship. *Biol Pharm Bull* 2003; 26: 468-473.
300. Alexander S. Flavonoids as antagonists at A<sub>1</sub> adenosine receptors. *Phytother Res* 2006; 20: 1009-1012.
301. Yamatake Y, Shibata M, Nagai M. Pharmacological studies on root bark of mulberry tree (*Morus alba* L.). *Jpn J Pharmacol* 1976; 26: 461-469.
302. El-Beshbishy H, Singab A, Sinkkonen J, Pihlaja K. Hypolipidemic and antioxidant effects of *Morus alba* L.(Egyptian mulberry) root bark fractions supplementation in cholesterol-fed rats. *Life Sci* 2006; 78: 2724-2733.
303. Du J, He Z, Jiang R, Ye W, Xu H, But P. Antiviral flavonoids from the root bark of *Morus alba* L. *Phytochemistry* 2003; 62: 1235-1238.
304. Hwang J, Shim J, Baek N, Pyun Y. Xanthorrhizol: a potential antibacterial agent from *Curcuma xanthorrhiza* against *Streptococcus mutans*. *Planta Med* 2000; 66: 196-197.
305. Yasni S, Imaizumi K, Sin K, Sugano M, Nonaka G. Identification of an active principle in essential oils and hexane-soluble fractions of *Curcuma xanthorrhiza* Roxb. showing triglyceride-lowering action in rats. *Food Chem Toxicol* 1994; 32: 273-278.
306. Morikawa T, Funakoshi K, Ninomiya K, Yasuda D, Miyagawa K, Matsuda H, Yoshikawa M. Medicinal foodstuffs. XXXIV. Structures of new prenylchalcones and prenylflavanones with TNF- $\alpha$  and aminopeptidase N inhibitory activities from *Boesenbergia rotunda*. *Chem Pharm Bull* 2008; 56: 956-962.
307. Magee A, Seabra M. Are prenyl groups on proteins sticky fingers or greasy handles? *Biochem J* 2003; 376: 3-4.
308. Nishiyama T, Mae T, Kishida H, Tsukagawa M, Mimaki Y, Kuroda M, Sashida Y, Takahashi K, Kawada T, Nakagawa K, Kitahara M. Curcuminoids and Sesquiterpenoids in Turmeric (*Curcuma longa* L.) Suppress an Increase in Blood Glucose Level in Type 2 Diabetic KK-Ay Mice. *J Agric Food Chem* 2005; 53: 959-963.
309. Ejaz A, Wu D, Kwan P, Meydani M. Curcumin Inhibits Adipogenesis in 3T3-L1 Adipocytes and Angiogenesis and Obesity in C57/BL Mice. *J Nutr* 2009; 139: 919-925.

310. Conley J. Nutmeg: Only a spice? In: Whitelaw W (ed.). *The proceedings of the 11th annual history of medicine days* Faculty of Medicine The University of Calgary Calgary 2002; 21 - 26.
311. Buriro M, Tayyab M. Effect of *Nigella sativa* on lipid profile in albino rats. *GJMS* 2007; 5: 28-31.
312. Le PM, Benhaddou-Andaloussi A, Elimadi A, Settaf A, Cherrah Y, Haddad PS. The petroleum ether extract of *Nigella sativa* exerts lipid-lowering and insulin-sensitizing actions in the rat. *J Ethnopharmacol* 2004; 94: 251-259.
313. Awale S, Tezuka Y, Banskota A, Kadota S. Siphonols A–E: Novel nitric oxide inhibitors from *Orthosiphon stamineus* of Indonesia. *Bioorg Med Chem Lett* 2003; 13: 31-35.
314. Awale S, Tezuka Y, Banskota A, Shimoji S, Taira K, Kadota S. Norstaminane- and isopimarane-type diterpenes of *Orthosiphon stamineus* from Okinawa. *Tetrahedron* 2002; 58: 5503-5512.
315. Tezuka Y, Stampoulis P, Banskota A, Awale S, Tran K, Saiki I, Kadota S. Constituents of the Vietnamese medicinal plant *Orthosiphon stamineus*. *Chem Pharm Bull* 2000; 48: 1711-1719.
316. Englert J, Harnischfeger G. Diuretic action of aqueous *Orthosiphon* extract in rats. *Planta Med* 1992; 58: 237-238.
317. Sriplang K, Adisakwattana S, Rungsipipat A, Yibchok-anun S. Effects of *Orthosiphon stamineus* aqueous extract on plasma glucose concentration and lipid profile in normal and streptozotocin-induced diabetic rats. *J Ethnopharmacol* 2007; 109: 510-514.
318. Poulsen S, Quinn R. Adenosine receptors: new opportunities for future drugs. *Bioorg Med Chem* 1998; 6: 619-641.
319. Modlinger P, Welch W. Adenosine A1 receptor antagonists and the kidney. *Curr Opin Nephrol Hypertens* 2003; 12: 497-502.
320. Spielman W, Arend L. Adenosine receptors and signaling in the kidney. *Hypertension* 1991; 17: 117-130.
321. Fruhbeck G, Gomez-Ambrosi J, Salvador J. Leptin-induced lipolysis opposes the tonic inhibition of endogenous adenosine in white adipocytes. *FASEB J* 2001; 15: 333-340.
322. Vannucci S, Klim C, Martin L, LaNoue K. A1-adenosine receptor-mediated inhibition of adipocyte adenylate cyclase and lipolysis in Zucker rats. *Am J Physiol Endocrinol Metab* 1989; 257: E871-878.
323. Xu B, Berkich DA, Crist GH, LaNoue KF. A1 adenosine receptor antagonism improves glucose tolerance in Zucker rats. *Am J Physiol Endocrinol Metab* 1998; 274: E271-279.
324. Cheng Y, Prusoff W. Relationship between the inhibition constant ( $K_i$ ) and the concentration of inhibitor which causes 50% inhibition ( $IC_{50}$ ) of an enzymatic reaction. *Biochem Pharmacol* 1973; 22: 3099-3108.
325. Moro S, van Rhee AM, Sanders LH, Jacobson KA. Flavonoid Derivatives as Adenosine Receptor Antagonists: A Comparison of the Hypothetical Receptor Binding Site Based on a Comparative Molecular Field Analysis Model. *J Med Chem* 1998; 41: 46-52.
326. Ji X, Melman N, Jacobson K. Interactions of flavonoids and other phytochemicals with adenosine receptors. *J Med Chem* 1996; 39: 781-788.
327. Chari V, Grayer-Barkmeijer R, Harborne J, Österdahl B. An acylated allose-containing 8-hydroxyflavone glycoside from *Veronica filiformis*. *Phytochemistry* 1981; 20: 1977-1979.
328. Iinuma M, Matsuura S, Kusuda K. <sup>13</sup>C-Nuclear magnetic resonance (NMR) spectral studies on polysubstituted flavonoids. I. <sup>13</sup>C-NMR spectra of flavones. *Chem Pharm Bull* 1980; 28: 708-716.
329. Kupchan S, Sigel C, Knox J, Udayamurthy M. Tumor inhibitors. XXXVI. Eupatin and eupatoretin, two cytotoxic flavonols from *Eupatorium semiserratum*. *J Org Chem* 1969; 34: 1460-1463.
330. Ingkaninan K, Ijzerman A, Verpoorte R. Luteolin, a compound with adenosine A1 receptor-binding activity, and chromone and dihydronaphthalenone constituents from *Senna siamea*. *J Nat Prod* 2000; 63: 315-317.
331. Wen X, Walle T. Methylated flavonoids have greatly improved intestinal absorption and metabolic stability. *Drug Metab Dispos* 2006; 34: 1786-1792.
332. Butler MS. The role of natural product chemistry in drug discovery. *J Nat Prod* 2004; 67: 2141-2153.
333. Dickson M, Gagnon JP. Key factors in the rising cost of new drug discovery and development. *Nat Rev Drug Discov* 2004; 3: 417-429.
334. Mishra KP, Ganju L, Sairam M, Banerjee PK, Sawhney RC. A review of high throughput technology for the screening of natural products. *Biomed Pharmacother* 2008; 62: 94-98.
335. Koehn FE, Carter GT. The evolving role of natural products in drug discovery. *Nat Rev Drug Discov* 2005; 4: 206-220.
336. Ortholand J-Y, Ganesan A. Natural products and combinatorial chemistry: back to the future. *Curr Opin Chem Biol* 2004; 8: 271-280.
337. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. *J Nat Prod* 2003; 66: 1022-1037.

## References

338. Wang M, Lamers R-JAN, Korthout HAAJ, van Nesselrooij JHJ, Witkamp RF, van der Heijden R, Voshol PJ, Havekes LM, Verpoorte R, van der Greef J. Metabolomics in the context of systems biology: bridging traditional Chinese medicine and molecular pharmacology. *Phytother Res* 2005; 19: 173-182.
339. Jahangir M, Kim HK, Choi YH, Verpoorte R. Metabolomic response of *Brassica rapa* submitted to pre-harvest bacterial contamination. *Food Chem* 2008; 107: 362-368.
340. McChesney JD, Venkataraman SK, Henri JT. Plant natural products: Back to the future or into extinction? *Phytochemistry* 2007; 68: 2015-2022.
341. Verpoorte R, Choi YH, Kim HK. Ethnopharmacology and systems biology: A perfect holistic match. *J Ethnopharmacol* 2005; 100: 53-56.
342. Li P, Qi L-W, Liu EH, Zhou J-L, Wen X-D. Analysis of Chinese herbal medicines with holistic approaches and integrated evaluation models. *Trends Anal Chem* 2008; 27: 66-77.
343. Ulrich-Merzenich G, Zeitler H, Jobst D, Panek D, Vetter H, Wagner H. Application of the "-Omic-" technologies in phytomedicine. *Phytomedicine* 2007; 14: 70-82.
344. Sumner LW, Mendes P, Dixon RA. Plant metabolomics: large-scale phytochemistry in the functional genomics era. *Phytochemistry* 2003; 62: 817-836.
345. Nisbet LJ, Moore M. Will natural products remain an important source of drug research for the future? *Curr Opin Biotechnol* 1997; 8: 708-712.
346. Verpoorte R. Exploration of nature's chemodiversity: the role of secondary metabolites as leads in drug development. *Drug Discov Today* 1998; 3: 232-238.
347. Pieters L, Vlietinck AJ. Bioguided isolation of pharmacologically active plant components, still a valuable strategy for the finding of new lead compounds? *J Ethnopharmacol* 2005; 100: 57-60.
348. Feher M, Schmidt JM. Property distributions: Differences between drugs, natural products, and molecules from combinatorial chemistry. *J Chem Inf Comput Sci* 2003; 43: 218-227.
349. Henkel T, Brunne RM, Müller H, Reichel F. Statistical investigation into the structural complementarity of natural products and synthetic compounds. *Angew Chem Int Ed* 1999; 38: 643-647.
350. Koehn FE. High impact technologies for natural products screening. *Natural Compounds as Drugs Volume I*: Birkhäuser Basel 2008; 175-210.
351. Schmid I, Sattler I, Grabley S, Thiericke R. Natural Products in High Throughput Screening: Automated High-Quality Sample Preparation. *J Biomol Screen* 1999; 4: 15-25.
352. Bindseil KU, Jakupovic J, Wolf D, Lavayre J, Leboul J, van der Pyl D. Pure compound libraries; a new perspective for natural product based drug discovery. *Drug Discov Today* 2001; 6: 840-847.
353. Verpoorte R, Kim H, Choi Y. Plants as source for medicines: New perspectives. In: Bogers R, Craker L, Lange D (eds.). *Medicinal and Aromatic Plants: Agricultural, Commercial, Ecological, Legal, Pharmacological and Social Aspects*. Wageningen UR: Wageningen 2006; 261-273.
354. Williard X, Pop I, Bourel L, Horvath D, Baudelle R, Melnyk P, Deprez B, Tartar A. Combinatorial chemistry: a rational approach to chemical diversity. *Eur J Med Chem* 1996; 31: 87-98.
355. Macarron R. Critical review of the role of HTS in drug discovery. *Drug Discov Today* 2006; 11: 277-279.
356. Myers PL. Will combinatorial chemistry deliver real medicines? *Curr Opin Biotechnol* 1997; 8: 701-707.
357. Gómez-Hens A, Aguilar-Caballos MP. Modern analytical approaches to high-throughput drug discovery. *Trends Anal Chem* 2007; 26: 171-182.
358. Bleicher KH, Böhm H-J, Müller K, Alanine AI. Hit and lead generation: beyond high-throughput screening. *Nat Rev Drug Discov* 2003; 2: 369-378.
359. Landro JA, Taylor ICA, Stirtan WG, Osterman DG, Kristie J, Hunnicutt EJ, Rae PMM, Sweetnam PM. HTS in the new millennium: The role of pharmacology and flexibility. *J Pharmacol Toxicol Methods* 2000; 44: 273-289.
360. Williams G. Advances in high throughput screening. *Drug Discov Today* 2004; 9: 515-516.
361. Smith A. Screening for drug discovery: The leading question. *Nature* 2002; 418: 453-459.
362. Bajorath J. Integration of virtual and high-throughput screening. *Nat Rev Drug Discov* 2002; 1: 882-894.
363. Entzeroth M. Emerging trends in high-throughput screening. *Curr Opin Pharmacol* 2003; 3: 522-529.
364. Liu L, Li Y-F, Cheng Y-Y. A method for the production and characterization of fractionated libraries from Chinese herbal formulas. *J Chromatogr B* 2008; 862: 196-204.
365. van Elswijk DA, Irth H. Analytical tools for the detection and characterization of biologically active compounds from nature. *Phytochem Rev* 2002; 1: 427-439.
366. Ingkaninan K, Hazekamp A, de Best CM, Irth H, Tjaden UR, van der Heijden R, van der Greef J, Verpoorte R. The application of HPLC with on-line coupled UV/MS: Biochemical detection for isolation of an acetylcholinesterase inhibitor from *Narcissus* Sir Winston Churchill. *J Nat Prod* 2000; 63: 803-806.
367. Schobel U, Frenay M, Van Elswijk DA, McAndrews JM, Long KR, Olson LM, Bobzin SC, Irth H. High resolution screening of plant natural product extracts for estrogen receptor  $\alpha$  and  $\beta$  binding activity using an online HPLC-MS biochemical detection system. *J Biomol Screen* 2001; 6: 291-303.

368. Schenk T, Breel GJ, Koevoets P, van Den Berg S, Hogenboom AC, Irth H, Tjaden UR, van Der Greef J. Screening of natural products extracts for the presence of phosphodiesterase inhibitors using liquid chromatography coupled online to parallel biochemical detection and chemical characterization. *J Biomol Screen* 2003; 8: 421-429.
369. Poulsen S, Davis R, Keys T. Screening a natural product-based combinatorial library using FTICR mass spectrometry. *Bioorg Med Chem* 2006; 14: 510-515.
370. Pavon FJ, Serrano A, Perez-Valero V, Jagerovic N, Hernandez-Folgado L, Bermudez-Silva FJ, Macias M, Goya P, de Fonseca FR. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: Effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats. *J Neuroendocrinol* 2008; 20: 116-123.
371. Beekwilder J, Jonker H, Meesters P, Hall RD, van der Meer IM, Ric de Vos CH. Antioxidants in raspberry; On-line analysis links antioxidant activity to a diversity of individual metabolites. *J Agric Food Chem* 2005; 53: 3313-3320.
372. Politi M, Chávez MI, Cañada FJ, Jiménez-Barbero J. Screening by NMR: A new approach for the study of bioactive natural products? The example of *Pleurotus ostreatus* hot water extract. *Eur J Org Chem* 2005; 2005: 1392-1396.
373. Exarchou V, Krucker M, van Beek TA, Vervoort J, Gerothanassis IP, Albert K. LC-NMR coupling technology: recent advancements and applications in natural products analysis. *Magn Reson Chem* 2005; 43: 681-687.
374. Wolfender J-L, Queiroz EF, Hostettmann K. The importance of hyphenated techniques in the discovery of new lead compounds from nature. *Expert Opin Drug Discovery* 2006; 1: 237-260.
375. Rollinger JM, Stuppner H, Langer T. Virtual screening for the discovery of bioactive natural products. In: Petersen F, Amstutz R (eds.). *Natural Compounds as Drugs Volume I*. Birkhäuser Verlag Basel 2008; 211-249.
376. Rochfort S. Metabolomics reviewed: A new omics platform technology for systems biology and implications for natural products research. *J Nat Prod* 2005; 68: 1813-1820.
377. Hall RD. Plant metabolomics: from holistic hope, to hype, to hot topic. *New Phytol* 2006; 169: 453-468.
378. Mendes P, Camacho D, de la Fuente A. Modelling and simulation for metabolomics data analysis. *Biochem Soc Trans* 2005; 33: 1427-1429.
379. Nobeli I, Thornton JM. A bioinformatician's view of the metabolome. *Bioessays* 2006; 28: 534-545.
380. Dunn WB, Ellis DI. Metabolomics: Current analytical platforms and methodologies. *Trends Anal Chem* 2005; 24: 285-294.
381. Moco S, Bino RJ, Vorst O, Verhoeven HA, de Groot J, van Beek TA, Vervoort J, de Vos CHR. A Liquid Chromatography-Mass Spectrometry-Based Metabolome Database for Tomato. *Plant Physiol* 2006; 141: 1205-1218.
382. Bhalla R, Narasimhan K, Swarup S. Metabolomics and its role in understanding cellular responses in plants. *Plant Cell Rep* 2005; 24: 562-571.
383. van der Greef J, Smilde AK. Symbiosis of chemometrics and metabolomics: past, present, and future. *J Chemometr* 2005; 19: 376-386.
384. Fiehn O. Metabolomics – the link between genotypes and phenotypes. *Plant Mol Biol* 2002; 48: 155-171.
385. Kell DB. Metabolomics and systems biology: making sense of the soup. *Curr Opin Microbiol* 2004; 7: 296-307.
386. Verpoorte R, Choi Y, Mustafa N, Kim H. Metabolomics: back to basics. *Phytochem Rev* 2008; 7: 525-537.
387. Fiehn O, Kopka J, Trethewey RN, Willmitzer L. Identification of uncommon plant metabolites based on calculation of elemental compositions using Gas Chromatography and Quadrupole Mass Spectrometry. *Anal Chem* 2000; 72: 3573-3580.
388. Tikunov Y, Lommen A, de Vos CHR, Verhoeven HA, Bino RJ, Hall RD, Bovy AG. A novel approach for nontargeted data analysis for metabolomics: Large-scale profiling of tomato fruit volatiles. *Plant Physiol* 2005; 139: 1125-1137.
389. Vaidyanathan S, Jones D, Broadhurst D, Ellis J, Jenkins T, Dunn W, Hayes A, Burton N, Oliver S, Kell D, Goodacre R. A laser desorption ionisation mass spectrometry approach for high throughput metabolomics. *Metabolomics* 2005; 1: 243-250.
390. Bifulco M, Grimaldi C, Gazziero P, Pisanti S, Santoro A. Rimonabant: Just an antiobesity drug? Current evidence on its pleiotropic effects. *Mol Pharmacol* 2007; 71: 1445-1456.
391. Thomas JJ, Shen Z, Crowell JE, Finn MG, Siuzdak G. Desorption/ionization on silicon (DIOS): A diverse mass spectrometry platform for protein characterization. *P Natl Acad Sci USA* 2001; 98: 4932-4937.
392. Ward JL, Baker JM, Beale MH. Recent applications of NMR spectroscopy in plant metabolomics. *FEBS J* 2007; 274: 1126-1131.



## References

393. Gabrielsson J, Jonsson H, Airiau C, Schmidt B, Escott R, Trygg J. OPLS methodology for analysis of pre-processing effects on spectroscopic data. *Chemom Intell Lab Syst* 2006; 84: 153-158.
394. Wold S, Trygg J, Berglund A, Antti H. Some recent developments in PLS modeling. *Chemom Intell Lab Syst* 2001; 58: 131-150.
395. Böröczky K, Laatsch H, Döbler IW, Stritzke K, Schulz S. Cluster analysis as selection and dereplication tool for the identification of new natural compounds from large sample sets. *Chem Biodiversity* 2006; 3: 622-634.
396. Cui Q, Lewis IA, Hegeman AD, Anderson ME, Li J, Schulte CF, Westler WM, Eghbalian HR, Sussman MR, Markley JL. Metabolite identification via the Madison Metabolomics Consortium Database. *Nat Biotech* 2008; 26: 162-164.
397. Schroeder FC, Gibson DM, Churchill ACL, Sojikul P, Wursthorn EJ, Krasnoff SB, Clardy J. Differential analysis of 2D NMR spectra: new natural products from a pilot-scale fungal extract library. *Angew Chem Int Ed* 2007; 119: 919-922.
398. Pierens GK, Palframan ME, Tranter CJ, Carroll AR, Quinn RJ. A robust clustering approach for NMR spectra of natural product extracts. *Magn Reson Chem* 2005; 43: 359-365.
399. Krug D, Zurek G, Revermann O, Vos M, Velicer GJ, Muller R. Discovering the hidden secondary metabolome of *Myxococcus xanthus*: a study of intraspecific diversity. *Appl Environ Microbiol.* 2008; 74: 3058-3068.
400. Wang Y, Tang H, Nicholson JK, Hylands PJ, Sampson J, Whitcombe I, Stewart CG, Caiger S, Oru I, Holmes E. Metabolomic strategy for the classification and quality control of phytomedicine: a case study of chamomile flower (*Matricaria recutita* L.). *Planta Med* 2004; 70: 250-255.
401. Choi YH, Kim HK, Hazekamp A, Erkelens C, Lefeber AWM, Verpoorte R. Metabolomic differentiation of *Cannabis sativa* cultivars using <sup>1</sup>H NMR spectroscopy and Principal Component Analysis. *J Nat Prod* 2004; 67: 953-957.
402. Choi YH, Sertic S, Kim HK, Wilson EG, Michopoulos F, Lefeber AWM, Erkelens C, Prat Kricun SD, Verpoorte R. Classification of *Ilex* species based on metabolomic fingerprinting using Nuclear Magnetic Resonance and Multivariate Data Analysis. *J Agric Food Chem* 2005; 53: 1237-1245.
403. Kim HK, Choi YH, Erkelens C, Lefeber AWM, Verpoorte R. Metabolic fingerprinting of *Ephedra* species using <sup>1</sup>H-NMR spectroscopy and Principal Component Analysis. *Chem Pharm Bull* 2005; 53: 105-109.
404. Rasmussen B, Cloarec O, Tang H, Staerk D, Jaroszewski JW. Multivariate analysis of integrated and full-resolution <sup>1</sup>H-NMR spectral data from complex pharmaceutical preparations: St. John's Wort. *Planta Med* 2006; 72: 556-563.
405. Ma C, Wang H, Lu X, Xu G, Liu B. Metabolic fingerprinting investigation of *Artemisia annua* L. in different stages of development by gas chromatography and gas chromatography-mass spectrometry. *J Chromatogr A* 2008; 1186: 412-419.
406. van der Kooy F, Verpoorte R, Marion Meyer JJ. Metabolomic quality control of claimed anti-malarial *Artemisia afra* herbal remedy and *A. afra* and *A. annua* plant extracts. *S Afr J Bot* 2008; 74: 186-189.
407. Yi L-z, Yuan D-l, Liang Y-z, Xie P-s, Zhao Y. Quality control and discrimination of Pericarpium Citri Reticulatae and Pericarpium Citri Reticulatae Viride based on high-performance liquid chromatographic fingerprints and multivariate statistical analysis. *Anal Chim Acta* 2007; 588: 207-215.
408. Shyur L-F, Yang N-S. Metabolomics for phytomedicine research and drug development. *Curr Opin Chem Biol* 2008; 12: 66-71.
409. Nicholson JK, Connelly J, Lindon JC, Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. *Nat Rev Drug Discov* 2002; 1: 153-161.
410. Jiang H, Xie Z, Koo HJ, McLaughlin SP, Timmermann BN, Gang DR. Metabolic profiling and phylogenetic analysis of medicinal *Zingiber* species: Tools for authentication of ginger (*Zingiber officinale* Rosc.). *Phytochemistry* 2006; 67: 1673-1685.
411. Leiss K, Choi Y, Abdel-Farid I, Verpoorte R, Klinkhamer P. NMR metabolomics of thrips (*Frankliniella occidentalis*) resistance in *Senecio* hybrids. *J Chem Ecol* 2009; 35: 219-229.
412. Biao-Yi Z, Yu Y, Zeng-Liang Y. Investigation of antimicrobial model of *Hemsleya pengxianensis* W.J. Chang and its main active component by metabolomics technique. *J Ethnopharmacol* 2008; 116: 89-95.
413. Wu B, Yan S, Lin Z, Wang Q, Yang Y, Yang G, Shen Z, Zhang W. Metabonomic study on ageing: NMR-based investigation into rat urinary metabolites and the effect of the total flavone of *Epimedium*. *Mol Biosyst* 2008; 4: 855-861.
414. Famei Li, Xiumei Lu, Huiping Liu, Man Liu, Zhili Xiong. A pharmaco-metabonomic study on the therapeutic basis and metabolic effects of *Epimedium brevicornum* Maxim on hydrocortisone-induced rat using UPLC-MS. *Biomed Chromatogr* 2007; 21: 397-405.
415. Zhao X, Zhang Y, Meng X, Yin P, Deng C, Chen J, Wang Z, Xu G. Effect of a traditional Chinese medicine preparation Xindi soft capsule on rat model of acute blood stasis: A urinary metabonomics study based on liquid chromatography-mass spectrometry. *J Chromatogr B* 2008; 873: 151-158.

416. Wang P, Liang Y, Zhou N, Chen B, Yi L, Yu Y, Yi Z. Screening and analysis of the multiple absorbed bioactive components and metabolites of Danggui-buxue decoction by the metabolic fingerprinting technique and liquid chromatography/diode-array detection mass spectrometry. *Rapid Commun Mass Spectrom* 2007; 21: 99-106.
417. Zhang X, Wu H, Liao P, Li X, Ni J, Pei F. NMR-based metabonomic study on the subacute toxicity of aristolochic acid in rats. *Food Chem Toxicol* 2006; 44: 1006-1014.
418. Li L, Sun B, Zhang Q, Fang J, Ma K, Li Y, Chen H, Dong F, Gao Y, Li F, Yan X. Metabonomic study on the toxicity of Hei-Shun-Pian, the processed lateral root of *Aconitum carmichaelii* Debx. (Ranunculaceae). *J Ethnopharmacol* 2008; 116: 561-568.
419. Mardiswijo S, Rajakmangunsudarso H. Cabe puyang, warisan nenek moyang. Jakarta: Balai Pustaka 1985.
420. Yuliana N, Khatib A, Link-Struensee A, Ijzerman A, Rungkat-Zakaria F, Choi Y, Verpoorte R. Adenosine A1 Receptor Binding Activity of Methoxy Flavonoids from *Orthosiphon stamineus*. *Planta Med* 2009; 75: 132-136.
421. Ingkaninan K, Hazekamp A, Hoek AC, Balconi S, Verpoorte R. Application of centrifugal partition chromatography in a general separation and dereplication procedure for plant extracts. *J Liq Chromatogr R T* 2000; 23: 2195 - 2208.
422. Eriksson L, Johansson E, Kettaneh-Wold N, Wold S. Multi-and megavariate data analysis: Umetrics Umeå 2001.
423. Romesburg C. Cluster analysis for researchers: Lulu Press 2004.
424. Wang B, Zhang Y, Li G, Guan H, Tong G. Fingerprint Chromatogram Analysis of Radix Glehniae by LC Coupled with Hierarchical Clustering Analysis. *Chromatographia* 2009; 70: 811-816.
425. Zou P, Hong Y, Koh H. Chemical fingerprinting of Isatis indigotica root by RP-HPLC and hierarchical clustering analysis. *J Pharm Biomed Anal* 2005; 38: 514-520.
426. Kim H, Choi Y, Verpoorte R. NMR-based metabolomic analysis of plants. *Nat Protoc* 2010; 5: 536-549.
427. Awale S, Tezuka Y, Banskota A, Kouda K, Tun K, Kadota S. Five novel highly oxygenated diterpenes of *Orthosiphon stamineus* from Myanmar. *J Nat Prod* 2001; 64: 592-596.
428. Asano N, Yamashita T, Yasuda K, Ikeda K, Kizu H, Kameda Y, Kato A, Nash RJ, Lee HS, Ryu KS. Polyhydroxylated Alkaloids Isolated from Mulberry Trees (*Morus alba* L.) and Silkworms (*Bombyx mori* L.). *J Agric Food Chem* 2001; 49: 4208-4213.
429. Nomura T, Fukai T, Katayanagi M. Studies on the constituents of the cultivated mulberry tree. III. Isolation of four new flavones, kuwanon A, B, C and oxydihydromorusin from the root bark of *Morus alba* L. *L Chem Pharm Bull (Tokyo)* 1978; 26: 1453-1458.
430. Schripsema J, Fung S, Verpoorte R. Screening of plant cell cultures for new industrially interesting compounds. In: DiCosmo F, Misawa M (eds.). *Plant cell culture secondary metabolism: Toward industrial application*. CRC Press: New York 1996; 1-10.
431. Duncan AC, Jäger AK, van Staden J. Screening of Zulu medicinal plants for angiotensin converting enzyme (ACE) inhibitors. *J Ethnopharmacol* 1999; 68: 63-70.
432. Droogmans S, Cosyns B, D'haenen H, Creten E, Weytjens C, Franken PR, Scott B, Schoors D, Kemdem A, Close L, Vandenbossche JL, Bechet S, Van Camp G. Possible association between 3,4-methylenedioxymethamphetamine abuse and valvular heart disease. *Am J Cardiol* 2007; 100: 1442-1445.
433. Trygg J, Wold S. Orthogonal projections to latent structures (O-PLS). *J Chemometr* 2002; 16: 119-128.
434. Eriksson L, Trygg J, Wold S. CV-ANOVA for significance testing of PLS and OPLS models. *J Chemometr* 2008; 22: 594-600.
435. Isabelle M, Lee BL, Ong CN, Liu X, Huang D. Peroxyl Radical Scavenging Capacity, Polyphenolics, and Lipophilic Antioxidant Profiles of Mulberry Fruits Cultivated in Southern China. *J Agric Food Chem* 2008; 56: 9410-9416.
436. Gerasopoulos D, Stavroulakis G. Quality characteristics of four mulberry (*Morus sp.*) cultivars in the area of Chania, Greece. *J Sci Food Agric* 1997; 73: 261-264.
437. Doi K, Kojima T, Makino M, Kimura Y, Fujimoto Y. Studies on the Constituents of the Leaves of *Morus alba* L. *Chem Pharm Bull* 2001; 49: 151-153.
438. Fu W, Lei YF, Cai YL, Zhou DN, Ruan JL. A new alkylene dihydrofuran glycoside with antioxidation activity from the root bark of *Morus alba* L. *Chin Chem Lett* 2010; 21: 821-823.
439. Nomura T, Fukai T, Hano Y, Urano S. Constituents of the Chinese Crude Drug 'Sāng-Bái-Pi' (*Morus* Root Bark). *Planta Med* 1983; 47: 95,99.
440. Piao SJ, Qiu F, Chen LX, Pan Y, Dou DQ. New Stilbene, Benzofuran, and Coumarin Glycosides from *Morus alba*. *Helv Chim Acta* 2009; 92: 579-587.
441. Tian HY, He X, Zeng GY, Tan JB, Li FS, Liu GR, Tan GS, Zhou YJ. A new prenylated arylbenzofuran derivative from *Morus alba* L. *Chin Chem Lett* 2010; 21: 329-331.

## References

442. Yang Y, Zhang T, Xiao L, Yang L, Chen R. Two new chalcones from leaves of *Morus alba* L. *Fitoterapia* 2010; 81: 614-616.
443. Zhang M, Wang R-R, Chen M, Zhang H-Q, Sun S, Zhang L-Y. A new flavanone glycoside with anti-proliferation activity from the root bark of *Morus alba*. *Chin J Nat Med* 2009; 7: 105-107.
444. Zhang Q-J, Ni G, Wang Y-H, Chen R-Y, Yu D-Q. Three new Diels-Alder type adducts from the stem bark of *Morus cathayana*. *J Asian Nat Prod Res* 2009; 11: 267 - 273.
445. Asano N, Oseki K, Tomioka E, Kizu H, Matsui K. N-containing sugars from *Morus alba* and their glycosidase inhibitory activities. *Carbohydr Res* 1994; 259: 243-255.
446. Kusano G, Orihara S, Tsukamoto D, Shibano M, Coskun M, Guvenc A, Erdurak C. Five new nortropane alkaloids and six new amino acids from the fruit of *Morus alba* L. growing in Turkey. *Chem Pharm Bull* 2002; 50: 185-192.
447. Dat NT, Binh PTX, Quynh LTP, Van Minh C, Huong HT, Lee JJ. Cytotoxic prenylated flavonoids from *Morus alba*. *Fitoterapia* 2010; In Press, Corrected Proof.
448. Sohn HY, Son KH, Kwon CS, Kwon GS, Kang SS. Antimicrobial and cytotoxic activity of 18 prenylated flavonoids isolated from medicinal plants: *Morus alba* L., *Morus mongolica* Schneider, *Broussonetia papyrifera* (L.) Vent, *Sophora flavescens* Ait and *Echinosophora koreensis* Nakai. *Phytomedicine* 2004; 11: 666-672.
449. Shin N-H, Ryu SY, Choi EJ, Kang S-H, Chang ILM, Min KR, Kim Y. Oxyresveratrol as the Potent Inhibitor on Dopa Oxidase Activity of Mushroom Tyrosinase. *Biochem Biophys Res Commun* 1998; 243: 801-803.
450. Kim JK, Kim M, Cho SG, Kim MK, Kim S, Lim YH. Biotransformation of mulberroside A from *Morus alba* results in enhancement of tyrosinase inhibition. *J Ind Microbiol Biot* 2010; 37: 631-637.
451. Hano Y, Goi K, Nomura T, Ueda S. Sequential glucosylation determined by NMR in the biosynthesis of mulberroside D, a cis-oxyresveratrol diglucoside, in *Morus alba* L. cell cultures. *Cell Mol Life Sci* 1997; 53: 237-241.
452. Takasugi M, Nagao S, Masamune T, Shirata A, Takahashi K. Structure of Moracin A and B, new phytoalexins from diseased mulberry. *Tetrahedron Lett* 1978; 19: 797-798.
453. Takasugi M, Nagao S, Masamune T, Shirata A, Takahashi K. Structures of moracins E, F, G, and H, new phytoalexins from diseased mulberry. *Tetrahedron Lett* 1979; 20: 4675-4678.
454. Matsuyama S, Kuwahara Y, Nakamura S, Suzuki T. Oviposition stimulants for the lesser mulberry pyralid, *Glyphodes pyloalis* (Walker), in mulberry leaves; rediscovery of phytoalexin components as insect kairomones. *Agric Biol Chem* 1991; 55: 1333-1341.
455. Yang Y, Gong T, Liu C, Chen R-Y. Four new 2-arylbenzofuran derivatives from leaves of *Morus alba* L. *Chem Pharm Bull* 2010; 58: 257-260.
456. Venkataraman K. Wood phenolics in the chemotaxonomy of the Moraceae. *Phytochemistry* 1972; 11: 1571-1586.
457. Venkatesh Kumar R, Chauhan S. Mulberry: Life enhancer. *J Med Pl Res* 2008; 2: 271-278.
458. Vu H, Pham N, Quinn R. Direct screening of natural product extracts using mass spectrometry. *J Biomol Screen* 2008; 13: 265.
459. Yuliana ND, Khatib A, Choi YH, Verpoorte R. Metabolomics for bioactivity assessment of natural products. *Phytother Res* 2010; Early preview.
460. Asano N, Tomioka E, Kizu H, Matsui K. Sugars with nitrogen in the ring isolated from the leaves of *Morus bombycis*. *Carbohydr Res* 1994; 253: 235-245.
461. Lee SH, Choi SY, Kim H, Hwang JS, Lee BG, Gao JJ, Kim SY. Mulberroside F isolated from the leaves of *Morus alba* inhibits melanin biosynthesis. *Biol Pharm Bull* 2002; 25: 1045-1048.
462. Oshima Y, Konno C, Hikino H, Matsushita K. Structure of moracenin B, a hypotensive principle of *Morus* root barks. *Tetrahedron Lett* 1980; 21: 3381-3384.
463. Park KM, You JS, Lee HY, Baek NI, Kuwanon G. Kuwanon G: an antibacterial agent from the root bark of *Morus alba* against oral pathogens. *J Ethnopharmacol* 2003; 84: 181-185.
464. Syah YM, Achmad SA, Ghisalberti EL, Hakim EH, Iman MZN, Makmur L, Mughaidin D. Andalasin A, a new stilbene dimer from *Morus macroura*. *Fitoterapia* 2000; 71: 630-635.
465. Takasugi M, Ishikawa S, Nagao S, Masamune T, Shirata A, Takahashi K. Albanins F and G, natural Diels-Alder adducts from mulberry. *Chem Lett* 1980; 9: 1577-1580.
466. Takasugi M, Nagao S, Masamune T. Structure of Dimoracin, a new natural Diels-Alder adduct from diseased mulberry. *Chem Lett* 1982; 11: 1217-1220.
467. van Elswijk D, Schobel P, Lansky E, Irth H, van der Greef J. Rapid dereplication of estrogenic compounds in pomegranate (*Punica granatum*) using on-line biochemical detection coupled to mass spectrometry. *Phytochemistry* 2004; 65: 233-241.
468. Bhushan R, Martens J. Direct resolution of enantiomers by impregnated TLC. *Biomed Chromatogr* 1997; 11: 280-285.

## **Acknowledgements**

---

When I was accepted as an MSc student in the Department of Pharmacognosy by Prof. Robert Verpoorte in August 2005, it was my start-point to uncover and to develop my other self-potentials. Learning so many new subjects in this department with his excellent supervision was such an exciting experience for me. The terms of NMR, metabolomics, bioactive compounds, and multivariate data analysis were introduced by Dr. Young Hae Choi and Dr. Hye Kyong Kim. Their guidance and advice in these subjects gave me invaluable insights. Prof. Adriaan P. IJzerman, Thea Mulder, and Henk de Vries from the Division of Medicinal Chemistry, Leiden/Amsterdam Center for Drug Research, had kindly given me permission to work in the C-Laboratory for the adenosine A1 and CB1 receptor bioassay while Dr. Henrie Korthout from Fyttagoras Plant Science BV had taught me to work with the CB1 receptor bioassay. Without all their support, it would have been impossible to do the medicinal plants chemical profiles and bioactivities correlation study.

I am grateful to the Committee of Phytochemical Society of Europe Joint Meeting 1999 Fund for financial support during my study. The project in this thesis was also partially funded by the Nobesinkas project.

I am thankful to Dr. Alfi Khatib as the first friend who helped me to get settled from the first day I arrived at Schiphol, and for his scientific support during the initial stage of my study until the first year of my PhD before he finally left for Malaysia.

I would also like to thank Dr. Muhammad Jahangir for all his support during my stay in Leiden, thank you for all fruitful scientific discussions and thank you for running my NMR samples no matter during weekends or other holidays.

I acknowledge Dr. Annelies Schulte for the Dutch translation of the summary of this thesis. I would like to thank Dr. Natalia Ria Mustafa for her encouragement especially when I missed my children. I also thank Dela, Nuning, and Dinar for being my best friends whenever I miss to speak in Bahasa. I am grateful to Dr. Teus Luijendijk for his kind assistance for many technical problems I encountered in the lab. I appreciate my Pakistani friends: Kashif, Muzamal, Tayyab, Yahya, and Nadeem for their hospitality, especially when I moved to my new home and needed some strong

## *Acknowledgements*

volunteers. From them I also learnt to spice up my food for a better taste and hopefully for a better health. I would like to thank Barbora, Andrea, and Justin for a very nice five years friendship. I also appreciate Roman, Qifang, Yuntao, Monica, Sonia, Nayra, Tatiana, Dalia, Paul, and all other international friends whose name are not mentioned here. Thank you for coloring my stay in Leiden with different cultures, different thoughts, I am lucky to know you and wish to see you again sometime somewhere.

Last but not the least, I would like to express my special thanks for some very special people in my life, to my Mama and Papa for their continuous love and prayer, and to my two little angels Amira and Khansa who have been very patiently waiting for me in Indonesia. I dedicate this work to you.

## Curriculum Vitae

---

Nancy Dewi Yuliana was born in 1970 in Tasikmalaya, West Java, Indonesia. During 1989 – 1994 she studied in Food Science and Technology Department, Bogor Agricultural University, Bogor, Indonesia. She investigated “The effect of different doses of cofactors and starch breaking-enzymes in the production of high fructose syrup from cassava starch” for her undergraduate research project. She completed her undergraduate studies in January 1994. In 2001 she decided to join the same department as a junior staff in Food Chemistry Division. In 2005, she was granted a STUNED scholarship from The Dutch Government to continue her study in The Pharmacognosy Department, Institute of Biology, Leiden University. She completed her MSc degree in 2007 with an MSc project entitled “Isolation of diuretic compounds from *Orthosiphon stamineus* Benth”. In the same year she continued her academic career by joining a PhD program in the same department for which she received a grant from the Phytochemical Society of Europe Joint Meeting 1999 Fund (PSE). During her PhD research, she developed a new tool for identification of active compounds from crude plant extract by integrating comprehensive extraction and NMR metabolomics.

Apart for her scientific career, since 2001 she has also been working as a halal auditor in The Assessment Institute for Food, Drugs, and Cosmetics (AIFDC), a non-governmental organization which issues halal certificates for food, drugs, and cosmetics in Indonesia under the supervision of Indonesian Council of Oulama. During her stay in Netherlands, she joined Halal Feed and Food Authority (HFFIA) which is a similar organization located in The Hague. Up to now, she has conducted halal audits in many multinational food industries in Asia, Australia, Europe, South America and USA.



## List of publications

---

1. Yuliana, N.D., Khatib, A., Link-Struensee, A.M.R., IJzerman, A.D., Zakaria, F.R., Choi, Y.H., Verpoorte, R. Adenosine A<sub>1</sub> binding activity of methoxy flavonoids from *Orthosiphon stamineus*. *Planta Medica* 2009: 75: 132 – 136.
2. Yuliana, N.D., Rosa, D., Korthout, H., Verpoorte, R. Screening of anti-obesity compounds from *Orthosiphon stamineus* with the CB1 assay. *Obesity Facts* 2009: 2 (supplement): 250.
3. Yuliana, N.D., Jahangir, M., Korthout, H., Choi, Y.H., Kim, H.K., Verpoorte, R. Comprehensive review on herbal medicine for energy intake suppression. Accepted in *Obesity Reviews*.
4. Yuliana, N.D., Khatib, A., Choi, Y.H., Verpoorte, R. Metabolomics for bioactivity assessment of natural products. *Phytotherapy Research* 2011: 25 (2); 157 – 169.
5. Yuliana, N.D., Iqbal, M., Jahangir, M., Wijaya, C.H., Korthout, H., Kottenhage, M., Kim, H.K., Verpoorte, R. Screening of selected Asian spices for anti obesity-related bioactivities. *Food Chemistry* 2011: 126 (4); 1724 – 1729.
6. Khatib, A., Yuliana, N.D., Jinap, S., Sarker, M.Z.I., Jaswir, I., Wilson, E.G., Chung, S.K., Verpoorte, R. Identification of possible compounds possessing Adenosine A<sub>1</sub> receptor binding activity in the leaves of *Orthosiphon stamineus* using TLC and multivariate data analysis. *Journal of Liquid Chromatography and Related Technologies* 2009: 32: 2906 – 2916
7. Lubbe, A., Khatib, A., Yuliana, N.D., Jinap, S., Verpoorte, R. Cannabinoid CB1 receptor binding and acetylcholinesterase inhibitory activity of *Sceletium tortuosum* L. *International Food Research Journal* 2010: 17: 349-355
8. Yuliana, N.D., Wijaya, C.H., Korthout, H., Kim, H.K., Verpoorte, R. Plant-derived food ingredients for stimulation of energy expenditure. (Accepted in *Critical Reviews in Food Science and Nutrition*).
9. Yuliana, N.D., Korthout, H., Andarwulan, N., Hariyadi, P., Kim, H.K., Verpoorte, R. A review on herbals with adipogenesis inhibition activity. (Submitted to *Obesity Facts*).
10. Yuliana, N.D., Khatib, A., Choi, Y.H., Verpoorte, R. Comprehensive extraction method integrated with NMR metabolomics - a new bioactivity screening procedure for plants: adenosine A<sub>1</sub> receptor binding compounds in *Orthosiphon stamineus* Benth. (In preparation to be submitted to *Analytical Chemistry*).